CA2220756A1 - Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously - Google Patents
Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously Download PDFInfo
- Publication number
- CA2220756A1 CA2220756A1 CA002220756A CA2220756A CA2220756A1 CA 2220756 A1 CA2220756 A1 CA 2220756A1 CA 002220756 A CA002220756 A CA 002220756A CA 2220756 A CA2220756 A CA 2220756A CA 2220756 A1 CA2220756 A1 CA 2220756A1
- Authority
- CA
- Canada
- Prior art keywords
- therapeutic
- transducer elements
- ultrasonic
- diagnostic
- vesicles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 140
- 238000000034 method Methods 0.000 title claims abstract description 46
- 238000002604 ultrasonography Methods 0.000 title abstract description 40
- 239000012867 bioactive agent Substances 0.000 claims abstract description 29
- 239000000463 material Substances 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 26
- 238000003491 array Methods 0.000 claims description 25
- 238000009472 formulation Methods 0.000 claims description 11
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000004593 Epoxy Substances 0.000 claims description 5
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 2
- 229920001084 poly(chloroprene) Polymers 0.000 claims description 2
- 239000011810 insulating material Substances 0.000 claims 1
- 238000003384 imaging method Methods 0.000 abstract description 34
- 150000002632 lipids Chemical class 0.000 description 22
- 239000000523 sample Substances 0.000 description 18
- 230000003993 interaction Effects 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 11
- 230000000087 stabilizing effect Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 206010020843 Hyperthermia Diseases 0.000 description 9
- 230000036031 hyperthermia Effects 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 7
- -1 aliphatic alcohols Chemical class 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 229920002477 rna polymer Polymers 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 238000002592 echocardiography Methods 0.000 description 3
- 230000009878 intermolecular interaction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 238000000429 assembly Methods 0.000 description 2
- 230000000712 assembly Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052451 lead zirconate titanate Inorganic materials 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- XJWSAJYUBXQQDR-UHFFFAOYSA-M dodecyltrimethylammonium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)C XJWSAJYUBXQQDR-UHFFFAOYSA-M 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- HFGPZNIAWCZYJU-UHFFFAOYSA-N lead zirconate titanate Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ti+4].[Zr+4].[Pb+2] HFGPZNIAWCZYJU-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- QPJSUIGXIBEQAC-UHFFFAOYSA-N n-(2,4-dichloro-5-propan-2-yloxyphenyl)acetamide Chemical compound CC(C)OC1=CC(NC(C)=O)=C(Cl)C=C1Cl QPJSUIGXIBEQAC-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960004692 perflenapent Drugs 0.000 description 1
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005610 quantum mechanics Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/12—Diagnosis using ultrasonic, sonic or infrasonic waves in body cavities or body tracts, e.g. by using catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
- A61B8/0833—Detecting organic movements or changes, e.g. tumours, cysts, swellings involving detecting or locating foreign bodies or organic structures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/44—Constructional features of the ultrasonic, sonic or infrasonic diagnostic device
- A61B8/4483—Constructional features of the ultrasonic, sonic or infrasonic diagnostic device characterised by features of the ultrasound transducer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/08—Detecting organic movements or changes, e.g. tumours, cysts, swellings
- A61B8/0883—Detecting organic movements or changes, e.g. tumours, cysts, swellings for diagnosis of the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/44—Constructional features of the ultrasonic, sonic or infrasonic diagnostic device
- A61B8/4444—Constructional features of the ultrasonic, sonic or infrasonic diagnostic device related to the probe
- A61B8/445—Details of catheter construction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01S—RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
- G01S15/00—Systems using the reflection or reradiation of acoustic waves, e.g. sonar systems
- G01S15/88—Sonar systems specially adapted for specific applications
- G01S15/89—Sonar systems specially adapted for specific applications for mapping or imaging
- G01S15/8906—Short-range imaging systems; Acoustic microscope systems using pulse-echo techniques
- G01S15/8909—Short-range imaging systems; Acoustic microscope systems using pulse-echo techniques using a static transducer configuration
- G01S15/8915—Short-range imaging systems; Acoustic microscope systems using pulse-echo techniques using a static transducer configuration using a transducer array
- G01S15/8925—Short-range imaging systems; Acoustic microscope systems using pulse-echo techniques using a static transducer configuration using a transducer array the array being a two-dimensional transducer configuration, i.e. matrix or orthogonal linear arrays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01S—RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES
- G01S15/00—Systems using the reflection or reradiation of acoustic waves, e.g. sonar systems
- G01S15/88—Sonar systems specially adapted for specific applications
- G01S15/89—Sonar systems specially adapted for specific applications for mapping or imaging
- G01S15/8906—Short-range imaging systems; Acoustic microscope systems using pulse-echo techniques
- G01S15/899—Combination of imaging systems with ancillary equipment
Abstract
Methods and apparatus (12-102) for performing diagnostic ultrasound simultaneously with the application of therapeutic ultrasonic waves are disclosed. The methods and apparatus (12-102) are particularly advantageous in performing ultrasonic imaging of a region of a patient while simultaneously applying therapeutic ultrasonic waves to the region for the purpose of rupturing vesicles administered to that region for purposes such as enhanced cavitation or the targeted release of a bioactive agent into the region. An operator is able to monitor the rupture of vesicles in real time.
Description
CA 022207~6 l997-ll-l2 W O 96~9079 PCTAUS96/07621 ~OvS AND APPARAT~S FOR PERrOK~ ~ DIAGNOSTIC AND
T~l7~pE~rIc ~.TRASOI~ND SIMm-TANriOu !~y RZ~CR~'RO~lND OF T~IE lNV ":N'l'lON
Field of the Invention The present invention relates to the fields of diagnostic and therapeutic ultrasound, and more particularly, to novel methods and apparatus for performing diagnostic ultrasound simultaneously with the application of therapeutic ultrasonic waves to a region of a patient.
10 Backqround of the Invention Diagnostic ultrasound refers to the imaging of a region of a human or ;~n;m~l patient using an ultrasound transducer to generate and receive ultrasonic waves.
Typically, the transducer is placed on the patient's body 15 over a region to be imaged and ultrasonic waves generated by the transducer are then directed at the region. The transducer then receives reflected ultrasonic waves from the region and converts the received waves into electrical signals from which an image is generated. Generally, better 20 images are obtained with diagnostic ultrasound when higher frequency, lower energy ultrasonic waves are employed.
Contrast agents can also be used to improve the quality of images obtained via diagnostic ultrasound. Exemplary contrast agents include, for example, suspensions of solid 25 particles, emulsified liauid droplets, and gas-filled bubbles. See , e . g ., Hilmann et al., U.S. Patent No.
4,466,442, and published International Patent Applications Wo 92/17212 and WO 92/21382.
W O 96/39079 PCT/U',~ 7621 Ultrasound has also been used in various therapeutic applications. One therapeutic use of ultrasound is known as hyperthermia. Hyperthermia involves insonating a targeted tissue mass, such as a tumor, with focused ultrasonic waves in order to heat the targeted mass.
Application of heat to the tissue mass results in a retardation of growth of, or a shrinking of, the mass. The heating effects of therapeutic ultrasound can be enhanced by the introduction of microbubbles into the region under treatment, as described in D~Arrigo, U.S. Patent No.
5,215,680.
Another therapeutic use of ultrasound, which is described in published International Patent Application WO
94/28873, involves administering a quantity of vesicles to a patient and monitoring the vesicles, for example using ~ diagnostic ultrasound, until the presence of the vesicles is detected in a region of interest. Therapeutic ultrasonic waves are then applied to the region in order to rupture the vesicles for therapeutic purposes. For example, the vesicles may be combined with a bioactive agent that is released upon rupture of the vesicles, thus achieving targeted delivery of the bioactive agent in the region of interest.
Therapeutic ultrasound is typically carried out at different frequencies than diagnostic ultrasound.
Specifically, it is desirable to perform therapeutic ultrasound at lower frequencies in order to achieve low attenuation, whereas higher fre~uencies are employed in diagnostic ultrasound to obtain better resolution.
There has been some effort in the prior art to provide systems that permit diagnostic ultrasound to be carried out simultaneously with therapeutic ultrasound, particularly therapeutic applications involving hyperthermia. Schaetzle, et al., U.S. Patent No. 5,391,140, describe an apparatus having a diagnostic ultrasound capability that operates simultaneously with the application of therapeutic acoustic waves for localized hyperthermia.
CA 022207~6 1997-11-12 W O 96/39079 PCT/U',.'07621 The system employs a transducer assembly that includes both diagnostic transducer elements and therapeutic tran~ducer elements. The diagnostic transducer elements form a central array that is surrounded by the therapeutic transducer elements. Placing the therapeutic transducer elements outwardly of the centrally located diagnostic transducer elements enables the therapeutic acoustic waves to be more accurately focused in hyperthermia applications to achieve greater heating of biological tissues. However, the central location of the diagnostic transducer elements limits image quality and resolution.
Driller et al., U.S. Patent No. 4,484,569, Coleman et al., U.S. Patent No. 4,932,414 and Wurster et al., U.S.
Patent No. 5,005,579 all describe various systems that combine diagnostic ultrasound capabilities with therapeutic, hyperthermia capabilities, although not necessarily simultaneously.
The transducer assemblies and systems employed in these prior art systems are relatively complex and expensive to manufacture. Moreover, to the extent that these systems may be capable of performing diagnostic and therapeutic ultrasound simultaneously, their therapeutic ultrasound capabilities are designed primarily for, and therefore limited to, use in hyperthermia applications. None of these systems are suitable for carrying out ultrasonic imaging simultaneously with the ultrasonic rupture of vesicles for purposes such as enhanced cavitation or the targeted delivery of a bioactive agent to a region of a patient.
Accordingly, methods and apparatus for providing such a capability are needed. The present invention satisfies this need.
~ SUMMARY OF THE lNV~LlON
The present invention is directed to novel methods ~ and apparatus for performing diagnostic ultrasound simultaneously with the application of therapeutic ultrasonic waves to a region of a patient. In particular, CA 022207~6 1997-11-12 W O 96/39079 PCT~US96/07621 the methods and apparatus of the present invention are advantageous in performing ultrasonic imaging of a region of a patient while simultaneously applying therapeutic ultrasonic waves to the region in order to rupture vesicles a~m;n;~tered to that region for various purposes, such as, for example, the targeted release of a bioactive agent combined with the vesicles. The methods and apparatus of the present invention allow an operator to monitor the rupture of vesicles in real time.
According to one aspect of the present invention, an ultrasonic transducer assembly comprises a plurality of therapeutic transducer elements for generating therapeutic ultrasonic waves, and a plurality of diagnostic transducer elements for generating and/or receiving diagnostic ultrasonic waves. The therapeutic and diagnostic transducer elements are arranged on a common platform having a substantially planar upper surface. The plurality of therapeutic transducer elements are disposed on the planar surface of the platform centrally of the plurality of diagnostic transducer elements. Placement of the plurality of diagnostic transducer elements outwardly from the centrally located plurality of therapeutic transducer elements enlarges the field of view of the ultrasonic transducer assembly, increases the imaging sensitivity of the assembly and increases the resolution of images obtained using the ultrasonic transducer assembly.
The ultrasonic transducer assembly of the present invention is capable of performing diagnostic ultrasound in a region of a patient simultaneously with the application of therapeutic ultrasonic waves to that region. The ultrasonic transducer assembly of the present invention can be used in a wide variety of therapeutic applications, including hyperthermia, cavitation and the like. The ultrasonic transducer assembly of the present invention is particularly advantageous for carrying out ultrasonic imaging of vesicles administered to a region of a patient simultaneously with the application of therapeutic ultrasonic waves in order to CA 022207~6 1997-11-12 W O 96~9079 PCT/U~ 7621 rupture the vesicles for purposes, such as, for example, the targeted release of a bioactive agent combined with the vesicles.
Another aspect of the present invention relates to a method of carrying out ultrasonic imaging simultaneously with the ultrasonic rupture of vesicles in a region of a patient for purposes, such as, for example, enhanced cavitation or the targeted delivery of a bioactive agent combined with the vesicles. The method comprises the steps of (i) administering to the patient a quantity of vesicles;
(ii) insonating the vesicles in a region of the patient with therapeutic ultrasonic waves at a frequency and energy to cause the vesicles to rupture; and (iii) simultaneously receiving ultrasonic emissions from the insonated vesicles at a harmonic of the frequency of the therapeutic ultrasonic waves and generating an image of said region from the received ultrasonic emissions. Simultaneous imaging allows an operator to monitor the rupture of the vesicles in real time.
These and other features and advantages of the present invention will become evident hereinafter.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing summary, as well as the following detailed description of the invention, is better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there is shown in the drawings embodiments that are presently preferred, it being understood, however, that the invention is not limited to the specific methods and instrumentalities disclosed. In the drawings:
Figure 1 is top view of a portion of an ultrasonic transducer assembly in accordance with one embodiment of the present invention;
Figure 2 is a cross-sectional view of the ultrasonic transducer assembly of Figure 1 taken along line 2-2 of Figure l;
CA 022207~6 1997-11-12 W O 96~9079 PCT/U',~'~7621 Figure 3 is a perspective view of the ultrasonic transducer assembly of Figure 2;
Figure 4 illustrates a second embodiment of an ultrasonic transducer assembly in accordance with the present invention;
Figure 5 shows a hand-held unit incorporating an ultrasonic transducer assembly of the present invention;
Figure 6 is a block diagram of apparatus for performing simultaneous diagnostic and therapeutic ultrasound using the ultrasonic transducer assembly of the present invention;
Figure 7 is a block diagram illustrating further details of the circuitry of Figure 6i Figure 8 illustrates a third embodiment of an ultrasonic transducer assembly in accordance with the present invention;
Figure 9 illustrates a fourth embodiment of an ultrasonic transducer assembly in accordance with the present invention;
Figures 10 (a) and (b) show a transesophageal probe incorporating an ultrasonic transducer assembly in accordance with the present invention;
Figures ll (a) and (b) show an intracavitary probe incorporating an ultrasonic transducer assembly in accordance with the present invention;
Figures 12 (a) and (b) show a second configuration of an intracavitary probe incorporating an ultrasonic transducer assembly in accordance with the present invention; and Figure 13 shows a third configuration of an intracavitary probe incorporating an ultrasonic transducer assembly in accordance with the present invention.
CA 022207~6 1997-11-12 W O 96~9079 ' PCT~US96/07621 DET~TT~n DESCRIPTION OF I~IE lNV~.l'ON
The present invention is directed to novel methods and apparatus for performing diagnostic ultrasound simultaneously with the application of therapeutic ultrasonic waves to a region of a patient. In particular, the methods and apparatus of the present invention are advantageous in performing ultrasonic imaging of a region of a patient while simultaneously applying therapeutic ultrasonic waves to the region for the purpose of rupturing vesicles administered to that region for various purposes, such as, for example, the targeted release of a bioactive agent into the region. The methods and apparatus of the present invention allow an operator to monitor the rupture of vesicles in real time.
As employed above and throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following m~n; ngs .
~ Lipid" refers to a synthetic or naturally-occurring amphipathic compound which comprises a hydrophilic component and a hydrophobic component. Lipids include, for example, fatty acids, neutral fats, phosphatides, glycolipids, aliphatic alcohols and waxes, terpenes and steroids.
"Lipid composition~ refers to a composition which comprises a lipid compound. Exemplary lipid compositions include suspensions, emulsions and vesicular compositions.
"Lipid formulation" refers to a composition which comprises a lipid compound and a bioactive agent.
~ Vesicle~ refers to a spherical entity which is characterized by the presence of an internal void.
Preferred vesicles are formulated from lipids, including the various lipids described herein. In any given vesicle, the lipids may be in the form of a monolayer or bilayer, and the mono- or bilayer lipids may be used to form one or more ~ 35 mono- or bilayers. In the case of more than one mono- or bilayer, the mono- or bilayers are generally concentric.
The lipid vesicles described herein include such entities CA 022207~6 1997-11-12 W O 96~9079 PCTrUS96/07621 commonly referred to as liposomes, micelles, bubbles, microbubbles, microspheres and the like. Thus, the lipids may be used to form a unilamellar vesicle (comprised of one monolayer or bilayer), an oligolamellar vesicle (comprised of about two or about three monolayers or bilayers) or a multilamellar vesicle (comprised of more than about three monolayers or bilayers). The internal void of the vesicles may be filled with a liquid, including, for example, an aqueous liquid, a gas, a gaseous precursor, and/or a solid or solute material, including, for example, a bioactive agent, as desired.
"Vesicular composition" refers to a composition which is formulated from lipids and which comprises vesicles.
"Vesicle formulation" refers to a composition which comprises vesicles and a bioactive agent.
"Liposome" refers to a generally spherical cluster or aggregate of amphipathic compounds, including lipid compounds, typically in the form of one or more concentric layers, for example, bilayers. They may also be referred to herein as lipid vesicles.
"Patient" refers to animals, including m~mm~l S, preferably humans.
"Bioactive agent" refers to a substance which ls used in connection with an application that is therapeutic or diagnostic in nature, such as in methods for diagnosing the presence or absence of a disease in a patient and/or in methods for the treatment of disease in a patient. As used herein, "bioactive agent'~ refers also to substances which are capable of exerting a biological effect in vitro and/or i~ vivo. The bioactive agents may be neutral or positively or negatively charged. Examples of suitable bioactive agents include diagnostic agents, pharmaceuticals, drugs, ,~
synthetic organic molecules, proteins, peptides, vitamins, steroids and genetic material, including nucleosides, nucleotides and polynucleotides.
CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 g "Diagnostic agent~ refers to any agent which is used in connection with methods for diagnosing the presence or absence of a disease in a patient. Exemplary diagnostic agents include, for example, contrast agents for use in 5 connection with ultrasound, magnetic resonance imaging or computed tomography of a patie~t, "Genetic materialn refers generally to nucleotides snd polynucleotide~, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The genetic material may be made by synthetic chemical methodology known to one of ordinary skill in the art, or by the use of recombinant technology, or by a combination of the two. The DNA and RNA
may optionally comprise llnn~t~ral nucleotides and may be single or double stranded. ~Genetic material" refers also to sense and anti-sense DNA and RNA, that is, a nucleotide sequence which is complementary to a specific sequence of nucleotides in DNA and/or RNA.
"Pharmaceutical" or ~drug~ refers to any therapeutic or prophylactic agent which is used in the treatment (including the prevention, diagnosis, alleviation, or cure) of a malady, affliction, disease or injury in a patient. Therapeutically useful peptides, polypeptides and polynucleotides are included within the me~n;ng of the term pharmaceutical or drug.
"Stabilizing material~ refers to a substance which is biocompatible and which i~ capable of promoting the formation of vesicles in a lipid composition. As used herein, ~stabilizing material" refers also to a substance which is biocompatible and which is capable of improving the stability of a vesicle. The stabilizing material may comprise a polymer. "Polymer", as used herein, refers to molecules formed from the chemical union of two or more repeating units. Accordingly, included within the term "polymer~ are, for example, dimers, trimers and oligomers.
The stabilizing material may also comprise a non-polymeric material, including, for example, monomeric molecules.
Encompassed also in the definition of ~stabilizing material"
CA 022207~6 1997-11-12 are certain of the present bioactive agents. The stabilizing material may be neutral or positively or negatively charged. Preferred among the neutral stabilizing materials are polar materials.
"Vesicle stability" refers to the ability of gas-filled vesicles to retain the gas entrapped therein after being exposed, for about one minute, to a pressure of about 300 mm Hg. Vesicle stability is measured in percent (~), this being the fraction of the amount of gas which is originally entrapped in the vesicle and which is retained after release of the pressure. Vesicle stability includes reference also to "vesicle resilience" which refers to the ability of a vesicle to return to its original size after release of the pressure.
"Viscosity" refers to the internal friction of a fluid that is measurable using st~n~rd viscosity-measuring means, such as a viscometer.
"Raising viscosity" refers to the increase of viscosity by greater than about 20~.
"Non-covalent association" refers to intermolecular interaction among two or more separate molecules, which interaction does not involve a covalent bond. Intermolecular interaction is dependent upon a variety of factors, including, for example, the polarity of the involved molecules, the charge (positive or negative), if any, of the involved molecules, and the like. Non-covalent associations are preferably selected ~rom the group consisting of ionic interaction, dipole-dipole interaction and van der Waal's forces and combinations thereof.
"Ionic interaction" refers to intermolecular interaction among two or more molecules, each of which is positively or negatively charged Thus, for example, ~'ionic interaction~ refers to the attraction between a first, positively charged molecule and a second, negatively charged molecule. Exemplary ionic interactions include, for example, the attraction between a negatively charged stabilizing material, for example, genetic material, and a CA 022207~6 1997-11-12 W O 96~9079 PCT/U~ v7621 positively charged lipid, for example, a cationic lipid, such as lauryltrimethylammonium bromide.
"Dipole-dipole interaction" refers generally to the attraction which can occur among two or more polar molecules. Thus, "dipole-dipole interaction" refers to the attraction of the positive end of a first polar molecule to the negative end of a second polar molecule. Dipole-dipole interactions are exemplified, for example, by the attraction between the electropositive head group, for example, the choline head group, of phosphatidylcholine and an electronegative atom, for example, a heteroatom, such as oxygen, nitrogen or sulphur, which is present in a stabilizing material, such as a polysaccharide. "Dipole-dipole interaction~ refers also to intermolecular hydrogen bonding in which a hydrogen atom serves as a bridge between electronegative atoms on separate molecules and in which a hydrogen atom is held to a first molecule by a covalent bond and to a second molecule by electrostatic forces.
"Van der Waal's forces" refers to the attractive forces between non-polar molecules that are accounted for by quantum mechanics. Van der Waal's forces are generally associated with momentary dipole moments which are induced by neighboring molecules and which involve changes in electron distribution.
Terms such as ~comprising a bioactive agent~ in combination with a bioactive agent," "combined with a bioactive agent" and the like, refer to the incorporation of a bioactive agent with a lipid composition. The bioactive agent can be combined with the lipid composition in any of a variety of ways. For example, when the lipid composition is in the form of a vesicular composition, the bioactive agent may be entrapped within the internal void of the vesicle.
The bioactive agent may also be integrated within the layer(s) or wall(s) o~ the vesicle, for example, by being interspersed among lipids which are contained within the vesicular layer(s) or wall(s). In addition, it is contemplated that the bioactive agent may be located on the CA 022207~6 1997-11-12 W O 96~9079 PCTrUS96/07621 surface of a vesicle. In this case, the bioactive agent may interact chemically with the surface of the vesicle and remain substantially adhered thereto. Such interaction may take the form of, for example, non-covalent association.
The interaction may result in the stabilization of the vesicle.
"Coat" or "coating" refers to the interaction of the stabilizing material with the lipid and/or vesicles and includes non-covalent interaction.
"Insonate" and variations thereof means to expose to ultrasonic waves.
Additional details concerning vesicles, vesicle compositions and vesicle formulations, including methods of producing the same, are provided in co-pending, commonly assigned, U.S. patent application Serial No. 08/417,238, filed April 5, 1995, entitled ~NOVEL COMPOSITIONS OF LIPIDS
AND STABILIZING MATERIALS", and in co-pending, commonly assigned, U.S. patent application Serial No. 08/076,250, filed June 11, 1993, entitled "NOVEL THERAPEUTIC DRUG
DELIVERY SYSTEMS", as well as their respective progeny, the disclosures of all of which are incorporated herein by reference in their entireties.
One aspect of the present invention is directed to an ultrasonic transducer assembly for performing diagnostic ultrasound in a region simultaneously with the application of therapeutic ultrasonic waves to the region. The ultrasonic transducer assembly of the present invention comprises a plurality of therapeutic transducer elements for generating therapeutic ultrasonic waves, and a plurality of diagnostic transducer elements for generating and/or receiving diagnostic ultrasonic waves. The therapeutic and diagnostic transducer elements are arranged on a common platform having a substantially planar upper surface. The plurality of therapeutic transducer elements are disposed on the planar surface of the platform centrally of the plurality of diagnostic transducer elements. Placement of the plurality of diagnostic transducer elements outwardly CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 from the centrally located plurality of therapeutic transducer elements enlarges the field of view of the ultrasonic transducer assembly, increases the imaging sensitivity of the assembly and increases the resolution of images obtained using the ultrasonic transducer assembly.
The ultrasonic transducer assembly of the present invention is capable of applying and receiving diagnostic ultrasonic waves to and from a region of a patient, simultaneously wit~ the application of therapeutic ultrasonic waves to that region. The ultrasonic transducer assembly of the present invention can be used in a wide variety of therapeutic applications, including hyperthermia, cavitation and the like. The ultrasonic transducer assembly of the present invention is particularly advantageous for carrying out ultrasonic imaging simultaneously with the ultrasonic rupture of vesicles for various purposes, such as, for example, ~nh~nced cavitation or the targeted release of bioa~ti-ve agen~s com~ined wi~h the vesicles. Wi~h ~he ultrasonic transducer assembly of the present invention, an operator can monitor the rupture of vesicles in real time.
Referring to the drawings wherein like numerals indicate like elements throughout, there is shown in Figure 1 a top view of a first embodiment of an ultrasonic transducer assembly 10 according to the present invention.
In accordance with this first embodiment, the plurality of therapeutic transducer elements comprises a linear array 16 of therapeutic transducer elements. AS used herein, the term "therapeutic transducer element" means a transducer element having acoustic properties suitable for generating ultrasonic waves at a frequency and energy useful in the practice of therapeutic ultrasound, and preferably having acoustic properties suitable for generating ultrasonic waves of a frequency and energy sufficient to rupture vesicles in vivo and/or in vitro. Preferably, the therapeutic transducer elements of the linear array 16 are capable of generating ultrasonic waves at a frequency in the range of about 0.25 to about 100 megahertz (MHz), more preferably in CA 022207~6 1997-11-12 W O 96/39079 PCT/U'5'1~7621 - 14 -the range of about 0.75 MHz to about 3.0 MHz, most preferably in the range of about 1.0 MHz to about 2.0 MHz.
The frequency at which a transducer element generates ultrasonic waves is, in part, a function of the thickness of the transducer element.
Further according to the first embodiment of the ultrasonic transducer assembly of the present invention, the second plurality of transducer elements comprises first and second linear arrays of diagnostic transducer elements 12 and 14, respectively, disposed on opposite sides of the linear array of therapeutic transducer elements 16. As used herein, the term "diagnostic transducer element" means a transducer element having acoustic properties suitable for generating and receiving acoustic signals in diagnostic ultrasound (imaging) applications, including those based on harmonic imaging techniques. Preferably, the diagnostic transducer elements of the first and second arrays 12, 14 are capable of generating and receiving ultrasonic waves at a frequency in the range of about 1.0 MHz to about 10.0 MHz.
Figure 2 is a cross-sectional view of the transducer assembly 10 of Figure 1, illustrating further details of the assembly 10 in accordance with the present embodiment. As shown, the respective linear arrays of transducer elements 12, 14, 16 are arranged on a common platform 18 having a substantially planar upper surface 18a.
In the present embodiment, a central portion of the upper surface 18a of the platform is stepped to accommodate the greater thickness of the linear array of therapeutic transducer elements 16. A first backing material 26 is disposed between the linear array of therapeutic transducer elements 16 and the upper surface 18a of the platform 18. A
second backing material 20 is disposed between each of the linear arrays of diagnostic transducer elements 12, 14 and the upper surface 18a of the platform. A common layer of an impedance matching material is provided on the opposite surfaces of each linear array of transducer elements 12, 14, 16, as shown.
CA 022207~6 1997-11-12 W O 96~9079 PCT/U~ 7621 The linear array of therapeutic transducer elements 16 can be operated in a continuous wave mode, or it can be operated in a pulse repetition frequency (PRF) mode selectable by an operator. The amount of energy supplied to the therapeutic transducer elements can be controlled by the operator, as can the depth of treatment. When employed as described below to rupture vesicles for therapeutic purposes, the linear array of therapeutic transducer elements 16 is preferably operated at energies in the range of 0. 05 to 5 ~ O W/cm2, and more preferably in the range of about 0.2 to about 2.5 W/cm2.
The first and second linear arrays of diagnostic transducer elements can be used to perform imaging tasks in a conventional manner and can be operated in several different modes. In one mode, each of the arrays 12, 14 is operated independently to create respective images on separate display screens simultaneously. In this mode, each linear array 12, 14 would transmit and receive its own ultrasonic waves. In another operating mode, one of the linear arrays 12, 14 can act as the transmitting array, and the other can act as the receiving array. The resultant image would be in the vicinity of the focal point of the array of therapeutic transducer elements 16. This modality would require conventional beam steering for proper focusing.
In a preferred imaging modality, described more fully below in connection with a novel method of the present invention, the linear array of therapeutic transducer elements 16 generates therapeutic ultrasonic waves having a frequency and energy sufficient to rupture a quantity of vesicles administered to a patient, and the two outer arrays of diagnostic transducer elements 12, 14 are used to receive ~ harmonic emissions from the insonated vesicles so that the vesicles can be imaged in real time as they rupture.
Preferably, the first and second arrays are used to receive second harmonic emissions from the insonated vesicles, i.e., emissions at twice the frequency of the incident, W O 96~9079 PCTAUS96/07621 therapeutic ultrasonic waves. However, receipt of emissionsat other harmonics of the incident waves, including both even and odd harmonics, can also be performed.
Both the therapeutic and diagnostic transducer elements are preferably formed of a ceramic piezoelectric material, such as, for example, lead zirconate titanate (PZT). Other piezoelectric materials can, however, be employed. As those skilled in the art know, the thickness and center-to-center spacing of adjacent transducer elements in a linear array determines the center, or resonant, frequency of the array. To achieve a desired center frequency, the thickness and center-to-center spacing of adjacent elements should be one-half the wavelength of an ultrasonic wave at that frequency. For example, for a desired center frequency of 3.5 MHz, the thickness and center-to-center spacing of adjacent transducer elements would be approximately 2.3xl0~2cm. The individual transducer elements of each array 12, 14, 16 can be formed in any conventional manner. For example, the transducer elements can be cut from a sheet of piezoelectric material using a diamond-bit saw, or alternatively, can be etched using a buffered solution of hydrofluoric acid (HF).
The first backing material 26 disposed between the linear array of therapeutic transducer elements 16 and the platform 18 preferably has an acoustic impedance suitable for the transmission of therapeutic ultrasonic waves. In the present embodiment, the first backing material preferably has an acoustic impedance in the range of about 2xl06 Kg/m2/s to about 3xl06 Kg/m2/s, which is suitable for transmission of therapeutic waves having frequencies and energies in the ranges set forth above. The first backing material may comprise any one of a variety of suitable materials. Preferably, the first backing material comprises a polymer matrix material that is bonded solidly to the linear array 16 of therapeutic transducer elements. For example, epoxy with tungsten powder can be used.
CA 022207~6 1997-11-12 W O 96/39079 PCTrUS96/07621 Alternatively, the first backing material 26 can comprise air.
The second backing material 20 disposed between each of the linear arrays of diagnostic transducer elements 12, 14 and the platform 18 preferably has an acoustic impedance suitable for the transmission and reception of diagnostic ultrasonic waves, preferably diagnostic ultrasonic waves having a fre~uency in the range of about 1.0 to about 10.0 MHz. Preferably, the second backing material has an acoustic impedance of about 7X106 Kg/m2/s.
The second backing material may comprise any one of a variety of suitable materials. Preferably, the second backing material comprises a polymer matrix material that is bonded solidly to the respective linear arrays 12, 14 of diagnostic transducer elements. For example, epoxy with tungsten powder may be used. Generally, the acoustic impedance of the first backing material 26 is lower than that of the second backing material 20.
The layer of matching material 24 preferably has an acoustic impedance that couples the mismatch of the acoustic impedance of the transducer elements to that of the biological tissue of the patient. Preferably, the matching material 24 has an acoustic impedance between that of the transducer elements and biological tissue. Any of a variety of suitable materials can be employed to form the matching layer 24, such as, for example, acrylic with epoxy.
Preferably, the therapeutic transducer elements 16 are isolated from the diagnostic transducer elements 12, 14 using a material that has a heavily damped acoustic impedance. Preferably, such a material would be located at areas 17 of the transducer assembly 10 of Figures 1 and 2.
An isolating material will reduce the acoustic interference , from the therapeutic transducer elements 16, which can add noise to the ultrasonic echos received by the diagnostic transducer elements 12, 14 during simultaneous imaging. A
variety of heavily damped materials can be employed as the isolating material, such as, for example, neoprene or air.
CA 022207~6 l997-ll-l2 W O 96~9079 PCTAUS96/07621 Figure 3 is a perspective view of the transducer assembly of Figure 2 illustrating the attachment of electrodes to the transducer elements of the respective linear arrays 12, 14, 16. Electrodes (not shown) on the top and bottom of each transducer element are connected to respective flexible circuit boards 28 and 30. The flexible circuit board 28 will connect one electrode on each transducer element to ground, and the other flexible circuit board 30 will connect the other electrode on each transducer element to an anode. Wire bonding or TA~3 bonding can be used to make the appropriate connections.
The number of elements in each linear array 12, 14, 16 is not limited to the number of elements illustrated in Figures 1 and 2. Figure 4 shows a second e~mbodiment of an ultrasonic transducer assembly 10' in accordance with the present invention. In this second embodiment, the ultrasonic transducer assembly has an increased number of elements in each linear array 12', 14', 16'. Increasing the number of transducer elements in each linear array 12, 14, 16 has the advantages of increased imaging resolution and higher therapeutic output.
Apodization techniques can be used with each linear array 12, 14, 16. Apodization will enhance contrast resolution and will eliminate side lobe artifacts in the linear arrays of diagnostic transducer elements 12, 14.
Apodization will also minimize side lobe artifacts in the linear array of therapeutic transducer elements 16.
Conventional beam steering techniques can be employed to focus the ultrasonic output of the linear array of therapeutic transducer elements 16, as well as to focus the linear arrays of diagnostic transducer elements 12, 14 in both transmit and receive modes. The m~; mllm angle for beam steering should be kept below 25 degrees to help minimize , grating lobes and side lobes that can affect image resolution.
Figure 5 shows a hand-held unit incorporating the ultrasonic transducer assembly 10 of the present invention.
CA 022207~6 1997-11-12 W O 96~9079 PCT/U',-1~7621 A housing 32 carries the transducer assembly 10 at one end.
A cable 36 connects the unit to an ultrasound system, described hereinafter in greater detail. A button 34 provides selective activation of the linear array of therapeutic transducer elements 16. The two arrays of diagnostic transducer elements 12, 14 can be used to locate a region to be treated. Once the desired region is located, the linear array of therapeutic transducer elements 16 can be activated by depressing the button 34.
The ultrasonic transducer assembly of the present invention, and the hand-held unit illustrated in Figure 5, are preferably constructed of non-magnetic materials that are compatible with magnetic resonance imaging (MRI) modalities. The contacts of the flexible circuits 28, 30 are preferably made of copper, or similar materials.
Housings are preferably made of non-magnetic materials such as stainless steel or a polymer material.
Figure 6 is a block diagram of an ultrasound system for use with the ultrasonic transducer assembly 10 of the present invention. A user interface 40 allows an operator to control various parameters, in a conventional manner, during both diagnostic and therapeutic operation of the transducer assembly 10. For example, the user can adjust the output energy of the transducer elements and can adjust the depth of focus of the emitted energy. A main system controller 42 controls the overall functioning of the ultrasound system, and can be implemented using a standard IBM PC/XT compatible board.
The main system controller 42 comm~n~.C a real time controller 44 to establish pulse train and timing parameters to achieve the desired diagnostic and therapeutic functions input by the operator. The real time controller 44 controls conventional focus modules 50, transmit/timing modules 52 and pulse/receiver modules 54 separately for the arrays of diagnostic and therapeutic transducer elements, e.g., linear arrays 12, 14 and 16. The focus modules 50, transmit/timing modules 52 and pulser/receiver modules 54 handle selection CA 022207~6 1997-11-12 W 096/39079 PCT~US96/07621 of the acoustic line of sight and focusing for both the diagnostic transducer arrays 12, 14 and the therapeutic transducer array 16. The transmit/timing modules 52 control the pulser/receiver modules 54 and enable the proper c~;3nnels to form appropriate apertures for both the diagnostic and therapeutic transducer arrays 12, 14, 16.
The pulser/receiver modules 54 generate the appropriate pulse trains for the individual transducer elements under control of the transmit/timing modules 52. Pulse width, duration, power, aperture size, and other parameter are controlled by the real time controller 44 in accordance with parameters input by the operator. For best imaging resolution, the ratio of focal distance to aperture size should be kept relatively low.
A high resolution monitor 48 provides the video display for the system. A video processor 45 serves as a selector and signal processor for acoustic echo information received by the diagnostic transducer arrays 12, 14. The video processor creates a single, analog stream of filtered, logarithmically compressed acoustic echo signals. Pre- and post-signal detection techniques, such as time gain compensation, are employed to compensate for attenuation versus penetration depth. A scan converter 46 converts the output of the video processor 45 into a signal compatible 2S with the monitor 48 to provide real-time display of two-~m~n~ional ultrasound images.
Figure 7 is a block diagram illustrating further details of the pulser/receiver modules 54 of Figure 6. A
pulser/receiver switch 56, which interfaces with the transmit/timing modules 52 and focus modules 50, controls the transmit and receive operations of the respective arrays of transducer elements 12, 14, 16. For a transmit operation, the pulser/receiver switch 56 sends signals to the appropriate pulser drivers 62, 64, 66. The pulser drivers 62, 64, 66 can be individually enabled via block 60.
Each transducer element of each array 12, 14, 16 is driven separately via respective element buses 74, 76, 78. The CA 022207~6 l997-ll-l2 W O 96~9079 PCTAUS96/07621 actual electrical signals are provided to the respective transducer elements by pulser circuits 68, 70 and 72. A
receiver multiplexer 80 controls the diagnostic transducer arrays 12, 14 in receive mode in order to "listen" for returned echos. When the diagnostic transducers 12, 14 are used in a transmit mode, the receiver multiplexer creates an open circuit to the receiver gain circuitry 82 so that the gain circuitry 82 does not get damaged.
RF filters 83 are employed to select a desired 10 frequency range for receiving returned echos via the diagnostic transducer elements 12, 14. An RF filter allows signals in a specified frequency range to pass while rejecting all other frequencies as noise. Because biological tissues act as a low-pass filter to incident 15 ultrasonic waves, when constructing an RF filter for maximum penetration, the RF filter should be designed with a center frequency that is below the center frequency of the diagnostic transducer elements.
Figure 8 illustrates a third embodiment of an 20 ultrasonic transducer assembly 84 in accordance with the present invention. In this third embodiment, the plurality of therapeutic transducer elements comprises a multiplexed phased array of therapeutic transducer elements 86, and the plurality of diagnostic transducer elements comprises a 25 multiplexed phased array of diagnostic transducer elements 88. As in the first and second embodiments, the array of therapeutic transducer elements 86 is disposed centrally of the array of diagnostic transducer elements on a common platform. Suitable backing and matching materials are 30 employed in the same manner as in the previous embodiments.
This embodiment can be used for treatment of areas close to the surface of a patient's skin.
Figure 9 illustrates a fourth embodiment of an ultrasonic transducer assembly 90 in accordance with the o 35 present invention. This fourth embodiment differs from the third embodiment in that the plurality of therapeutic transducer elements comprise an annular array of therapeutic CA 022207~6 1997-11-12 transducer elements 92. As in the previous embodiments, the annular array of therapeutic transducer elements 92 iS
disposed centrally of the array of diagnostic transducer elements 94 on a common platform. Suitable backing and matching materials are employed in the same manner as in the previous embodiments. This embodiment can be used for treatment close to the surface of a patient's skin and for treatment to medium depths.
As those skilled in the art can appreciate, the circuitry of Figures 6 and 7 must be modified in a conventional manner to operate with the multiplexed phased transducer arrays of the third and fourth embodiments.
In each of the foregoing embodiments, the therapeutic transducer elements are disposed centrally of the diagnostic transducer elements. Placing the diagnostic transducer elements outwardly from the centrally located therapeutic elements enlarges the field of view of the transducer assembly, increases the imaging sensitivity of the assembly and increases the resolution of images obtained using the transducer assembly.
The ultrasonic transducer assembly of the present invention can be incorporated into specialized ultrasonic probes to enable an operator to bring the transducer assembly closer to anatomical regions of interest. In this manner tissue differentiation can be more easily discerned, and an enhanced resolution and wider field of view can be achieved.
Figures 10 (a) and (b) show different views of a transesophageal probe 96 incorporating a transducer assembly in accordance with any one of the foregoing embodiments lO, 10', 84, 90 of the present invention. The transducer assembly is placed at the tip of the probe. The transesophageal probe can be used for imaging tissues and the heart from within the esophagus. The ultrasonic transducer assembly can be rotated manually through an angle of approximately 180 degrees. The transducer assembly can also be rotated in the anterior and posterior directions at CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 angles of up to 120 degrees. The transducer assembly can still further be moved/rotated to the left and right with an angle of rotation of up to 90 degrees.
Figures 11 (a) and (b) show different views of one configuration of an intracavitary probe 98 incorporating a transducer assembly in accordance any one of the embodiments 10, 10', 84, 90 described above. The intracavitary probe 98 of Figures 11 (a) and (b) can be used in endovaginal applications. As best shown in Figure 11, the platform of the transducer assembly can be contoured to suit the particular application.
Figures 12 (a) and (b) show different views of a second configuration of an intracavitary probe 100 incorporating a transducer assembly in accordance with any one of the foregoing embodiments. In this configuration, the transducer assembly is located at the extreme tip of the probe 100. Such a configuration can be used in endovaginal applications, or can be used for imaging the prostate.
Figure 13 shows a third configuration of an intracavitary probe 102 incorporating a transducer assembly in accordance with any one of the foregoing embodiments. In this configuration, the transducer assembly encircles the shaft of the probe just below the tip. This configuration can be used for either endovaginal or endorectal imaging.
According to another aspect of the present invention, a novel method is provided wherein ultrasonic imaging of vesicles in a region of a patient is carried out simultaneously with the application of therapeutic ultrasonic waves in order to rupture the vesicles for purposes, such as, for example, enhanced cavitation or the targeted release of a bioactive agent combined with the vesicles. The method comprises the steps of (i) administering to the patient a quantity of vesicles; (ii) insonating the vesicles in a region of the patient with therapeutic ultrasonic waves at a frequency and energy to cause the vesicles to rupture; and (iii) simultaneously receiving ultrasonic emissions from the insonated vesicles CA 022207~6 1997-11-12 W O 96/39079 PCT~US96/07621 at a harmonic of the frequency of the therapeutic ultrasonic waves and generating an image of said region from the received ultrasonic emissions. Simultaneous imaging allows an operator to monitor the rupture of the vesicles in real time.
As one skilled in the art would recognize once armed with the present disclosure, widely varying amounts of vesicles may be employed in the practice of the method of the present invention. As used herein, the term "quantity of vesicles" is intended to encompass all such amounts.
It is known that bubbles suspended in a liquid, such as the administered vesicles described herein, can be made to emit ultrasonic energy when exposed to ultrasonic waves. See, e.g., D.L. Miller, ~Ultrasonic Detection of Resonant Cavitation Bubbles in a Flow Tube by their Second Harmonic Emissions," Ultrasonics, pp. 217-224 (September 1981), the disclosure of which is hereby incorporated by reference. Emission of ultrasonic energy occurs at harmonics of the incident frequency. The method of the present invention takes advantage of this known property to allow an operator to image the vesicles of a vesicle formulation simultaneously with the application of therapeutic ultrasonic waves for the purpose of rupturing the vesicles. The therapeutic ultrasonic waves serve to produce the harmonic emissions in the vesicles prior to their rupture.
Emission at twice the frequency of the incident ultrasonic waves, called second harmonic emissions, are the strongest harmonic emissions at low amplitudes. Preferably, it is these so-called second harmonic emissions that are received in the aforementioned receiving step. It is desirable where possible to insonate the vesicles at a frequency which is close to optimal for eliciting maximal second harmonic signals, and this will vary depending upon the diameter, elasticity, and density of the vesicles. Of course, imaging can be performed at other harmonic frequencies, including both even and odd harmonic CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 frequencies, if desired. Imaging at harmonics and sub-harmonics of an excitation frequency is described in U.S.
Patent No. 5,410,516, the disclosure of which is hereby incorporated by reference in its entirety.
In order to achieve rupture of the vesicles, continuous wave therapeutic ultrasound is preferred, although the sound energy may be pulsed also. If pulsed sound energy is used, the sound will generally be pulsed in echo train lengths of about 8 to about 20 or more pulses at a time. Preferably, the echo train lengths are about 20 _ pulses at a time.
Energy levels of the therapeutic ultrasonic waves used to insonate the vesicles are preferably in the range of about 0.05 Watt (W) per square centimeter (cm2) to about 5.0 W/cm2, with energy levels of about 0.2 to about 2.5 W/cm2 being preferred. For very small vesicles, for example, vesicles having a diameter of less than about 0.5 micron, higher frequency ultrasonic waves are generally preferred.
This is because smaller vesicles are capable of absorbing ultrasonic energy more effectively at higher frequencies.
External application may be preferred for the skin and other superficial tissues, but for deep structures, the application of sonic energy via interstitial probes or intracavitary probes o~ the type described above may be preferred.
Experiments have shown that the onset of vesicle rupture occurs at the following spatial peak temporal average intensities (ISPTA)~ in milli-Watts (mW) per centimeter squared (cm2), for continuous-wave and selected duty cycles of ultrasonic waves. All values were obtained using a ultrasonic waves having a frequency of 1.0 MHz.
Duty Cycles ISPTA (mW/cm 5.3~ 290 10.4~ 100 21.9~ 70 CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 ¦¦ Continuous Wave ¦ 35 As these data reveal, rupture occurs most easily with continuous wave ultrasound.
Vesicles can be administered to the patient in a variety of forms adapted to the chosen route of administration, namely, parenterally, orally, or intraperitoneally. Parenteral administration, which is preferred, includes administration by the following routes:
intravenous; intramuscular; interstitially; intra-arterially; subcutaneous; intraocular; intrasynovial;transepithelial, including transdermal; pulmonary via inhalation; ophthalmic; sublingual and buccali topically, including ophthalmic; dermal; ocular; rectal; and nasal inhalation via insufflation. Intravenous administration is preferred among the routes of parenteral administration.
The useful dosage to be ~m; n; stered and the mode of administration will vary depending upon the age, weight, and type of ~n; m~l to be treated, and the particular therapeutic application intended. Typically, dosage is initiated at lower levels and increased until the desired therapeutic effect is achieved.
The patient may be any type of animal, but is preferably a vertebrate, more preferably a m~mm~l, and most preferably human. By region of a patient, it is meant the whole patient, or a particular area or portion of the patient.
The method of the present invention can also be carried out ln ~itro. For example, in cell culture applications, the vesicles may be added to the cells in cultures and then incubated. Therapeutic ultrasonic waves can then be applied to the culture media containing the cells and vesicles.
The method of the present invention is most advantageously carried out using the novel ultrasonic transducer assemblies of the present invention. For example, considering the ultrasonic transducer assembly 10 CA 022207~6 l997-ll-l2 W O 96/39079 PCTrUS96/07621 of Figure 1, the linear array of therapeutic transducer elements 16 can be used to perform the insonating step at a first frequency, such as 1.75 MHz, while the first and second linear arrays of diagnostic transducer elements 12, 14 can be fabricated and employed to receive the harmonic emissions of the vesicles at twice the incident frequency, i.e., 3.5 MHz.
EX~PLES
The method of the present invention is further described in the following prophetic examples. These prophetic examples are for illustrative purposes only, and are not to be construed as limiting the appended claims.
Exaunple 1 In a patient with a malignant soft tissue sarcoma of the thigh, 5.0 cubic centimeters (cc) of a vesicle formulation, 1.5X109 vesicles/milliliter (ml), combining 5 milligrams (mg) of doxorubicin is injected intravenously (IV). The patient~s tumor is ultrasonically imaged via a plurality of diagnostic transducer elements. As the vesicles pass through the tumor's microvasculature, they are detected via gray scale imaging and color Doppler. Upon detection, therapeutic ultrasonic waves are applied in bursts of 10 seconds using continuous wave ultrasound at a frequency of 1. 5 MHz and energy of o. 5 W/cm2 ~ The diagnostic transducer elements are employed to receive second harmonic emissions from the vesicles at a frequency of 3.0 MHz, twice the incident frequency of the therapeutic ultrasonic waves.
As the vesicles rupture, the doxorubicin is released locally within the tumor. Simultaneous imaging in accordance with the methods and apparatus of the present invention allows the physician to monitor the rupture of vesicles in real-time. High intra-tumoral concentrations o~ chemotherapy are attained, and the patient~s tumor is eradicated.
Exaunple 2 CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 In a patient with breast cancer, 5.0 cc of a vesicle formulation comprising perfluoropentane vesicles labeled with antibodies to breast cancer epitopes is injected IV. Approximately 48 hours later, ultrasonic imaging of the patient's axilla is performed. A plurality of therapeutic transducer elements are employed to generate incident ultrasonic waves at a frequency insufficient to cause vesicle rupture, but sufficient to produce second harmonic emissions. Once second harmonic emissions are received from lymph nodes binding the antibody bearing vesicles, the energy of the therapeutic ultrasonic waves is increased to 5.0 W/cm2. The tumor bonded with vesicles lowers the cavitation threshold and local intra nodal cavitation is achieved destroying the malignant tumor.
Simultaneous imaging of the destruction is achieved via the plurality of diagnostic transducer elements.
Example 3 The same as example 2, except that the vesicles also contain 1.0 mg per ml of cis-platinum. A lower energy of 0.5 W/cm2 is applied to rupture the vesicles and release the cis-platinum within the lymph nodes, destroying the tumor.
Example 4 In a patient with myocardial ischemia involving the left anterior wall, 2.0 cc of cationic vesicles (1.0x109 vesicles/ml) binding the gene for endothelial growth factor (EFG) is injected IV. Continuous wave therapeutic ultrasound is applied in bursts at energies of between 0.05 and 0.2 W/cm2 to the le~t ventricular anterior wall myocardium. As the vesicles pass through the microvasculature of the anterior wall myocardial tissue, the vesicles are ruptured. Rupture o~ the vesicles not only releases the genes into the myocardium but also creates local shock waves which facilitate passage of the genetic material into the cardiac endothelial and myocyte cells.
W O 96/39079 PCT/U','/~7621 Local gene expression into EFG is achieved with resultant growth of new coronary circulation and improvement in coronary blood flow. Rupture of the vesicles is monitored in real time via the second harmonic emissions received by a plurality of diagnostic transducer elements.
Example 5 A patient with locally invasive esophageal cancer is treated with bubbles bearing mitomycin-C and the gene for BCL-2. An endoesophageal transducer, such as the probe lo illustrated in Figures lO(a) and (b), is placed in the esophagus and the position of the transducer is confirmed via the plurality of diagnostic transducer elements. A lO.o ml vesicle formulation binding drug and genetic material is then injected IV. As the vesicles pass through the tumor they are ruptured using bursts of O.S W/cm2 therapeutic ultrasonic waves. Rupture of the vesicles is monitored in real time. The therapy results in elimination of the tumor.
Example 6 As in example 5, except that the patient has pancreatic cancer. The transducer assembly is placed into the stomach and positioned such that imaging is performed through the posterior wall of the stomach. The pancreatic tumor is localized, the vesicle formulation is injected as in example 5, and therapy is performed while simultaneously imaging the rupture of the vesicles. The patient achieves a remission of pancreatic carcinoma.
Example 7 A patient with atherosclerosis is administered a 5.0 cc vesicle formulation having vesicles less than 1.0 micrometer (~m) in diameter, which are labeled with cholesterol. The vesicles accumulate in regions of lipid laden plaque. Transcutaneous therapeutic ultrasonic waves are then applied with an energy of 0.5 W/cm2. The vesicles CA 022207~6 1997-11-12 rupture as they lyse the plaque. Rupture of the vesicles is =
monitored in real-time.
Example 8 As in example 7, except that the vesicles are targeted to the atherosclerotic plaque by labeling with low density lipoproteins (LPL).
Example 9 As in example 7, except that the antisense construct to basic fibroblastic growth factor is applied to eliminate intimal hyperplasia and restenosis.
Example 10 As in examples 7 and 8, except that an endovascular catheter equipped with an ultrasonic transducer assembly is employed. The vesicles within the arterial plaque are then burst from within the vessel using the therapeutic transducer elements on the endovascular catheter.
Example 11 In a patient with prostate cancer, 10 ml of a vesicle formulation binding 10 mg of anti LHRH decapeptide are injected IV. An endorectal probe with an ultrasonic transducer assembly of the present invention is placed within the rectum and positioned adjacent the prostate gland with the aid of the diagnostic transducer elements. As the vesicles are detected coursing within the microvasculature of the prostatic tumor, high energy therapeutic ultrasonic waves are applied, and the vesicles are ruptured, releasing high local concentrations of the inhibitory peptide.
Simultaneous imaging of the vesicles is performed via second harmonic emissions. Tumor regression is thus achieved ~rom an outpatient, minimally invasive procedure.
The disclosures of each patent, patent applicationand publication cited or described in this document are hereby incorporated by reference, in their entirety.
As the foregoing illustrates, the present invention is directed to novel methods and apparatus for performing diagnostic ultrasound simultaneously with the application of therapeutic ultrasonic waves to a region of a patient. In particular, the methods and apparatus o~ the present invention are advantageous in performing ultrasonic imaging of a region of a patient while simultaneously applying therapeutic ultrasonic waves to the region in order to rupture vesicles in the region for therapeutic purposes, such as, for example, the targeted release of a bioactive agent. The methods and apparatus of the present invention allow an operator to monitor the rupture of vesicles in real time. It is understood that changes may be made to the embodiments described above without departing from the broad inventive concepts thereof. Accordingly, the present invention is not limited to the particular embodiments disclosed, but is intended to cover all modifications that are within the spirit and scope of the invention as defined by the appended claims.
T~l7~pE~rIc ~.TRASOI~ND SIMm-TANriOu !~y RZ~CR~'RO~lND OF T~IE lNV ":N'l'lON
Field of the Invention The present invention relates to the fields of diagnostic and therapeutic ultrasound, and more particularly, to novel methods and apparatus for performing diagnostic ultrasound simultaneously with the application of therapeutic ultrasonic waves to a region of a patient.
10 Backqround of the Invention Diagnostic ultrasound refers to the imaging of a region of a human or ;~n;m~l patient using an ultrasound transducer to generate and receive ultrasonic waves.
Typically, the transducer is placed on the patient's body 15 over a region to be imaged and ultrasonic waves generated by the transducer are then directed at the region. The transducer then receives reflected ultrasonic waves from the region and converts the received waves into electrical signals from which an image is generated. Generally, better 20 images are obtained with diagnostic ultrasound when higher frequency, lower energy ultrasonic waves are employed.
Contrast agents can also be used to improve the quality of images obtained via diagnostic ultrasound. Exemplary contrast agents include, for example, suspensions of solid 25 particles, emulsified liauid droplets, and gas-filled bubbles. See , e . g ., Hilmann et al., U.S. Patent No.
4,466,442, and published International Patent Applications Wo 92/17212 and WO 92/21382.
W O 96/39079 PCT/U',~ 7621 Ultrasound has also been used in various therapeutic applications. One therapeutic use of ultrasound is known as hyperthermia. Hyperthermia involves insonating a targeted tissue mass, such as a tumor, with focused ultrasonic waves in order to heat the targeted mass.
Application of heat to the tissue mass results in a retardation of growth of, or a shrinking of, the mass. The heating effects of therapeutic ultrasound can be enhanced by the introduction of microbubbles into the region under treatment, as described in D~Arrigo, U.S. Patent No.
5,215,680.
Another therapeutic use of ultrasound, which is described in published International Patent Application WO
94/28873, involves administering a quantity of vesicles to a patient and monitoring the vesicles, for example using ~ diagnostic ultrasound, until the presence of the vesicles is detected in a region of interest. Therapeutic ultrasonic waves are then applied to the region in order to rupture the vesicles for therapeutic purposes. For example, the vesicles may be combined with a bioactive agent that is released upon rupture of the vesicles, thus achieving targeted delivery of the bioactive agent in the region of interest.
Therapeutic ultrasound is typically carried out at different frequencies than diagnostic ultrasound.
Specifically, it is desirable to perform therapeutic ultrasound at lower frequencies in order to achieve low attenuation, whereas higher fre~uencies are employed in diagnostic ultrasound to obtain better resolution.
There has been some effort in the prior art to provide systems that permit diagnostic ultrasound to be carried out simultaneously with therapeutic ultrasound, particularly therapeutic applications involving hyperthermia. Schaetzle, et al., U.S. Patent No. 5,391,140, describe an apparatus having a diagnostic ultrasound capability that operates simultaneously with the application of therapeutic acoustic waves for localized hyperthermia.
CA 022207~6 1997-11-12 W O 96/39079 PCT/U',.'07621 The system employs a transducer assembly that includes both diagnostic transducer elements and therapeutic tran~ducer elements. The diagnostic transducer elements form a central array that is surrounded by the therapeutic transducer elements. Placing the therapeutic transducer elements outwardly of the centrally located diagnostic transducer elements enables the therapeutic acoustic waves to be more accurately focused in hyperthermia applications to achieve greater heating of biological tissues. However, the central location of the diagnostic transducer elements limits image quality and resolution.
Driller et al., U.S. Patent No. 4,484,569, Coleman et al., U.S. Patent No. 4,932,414 and Wurster et al., U.S.
Patent No. 5,005,579 all describe various systems that combine diagnostic ultrasound capabilities with therapeutic, hyperthermia capabilities, although not necessarily simultaneously.
The transducer assemblies and systems employed in these prior art systems are relatively complex and expensive to manufacture. Moreover, to the extent that these systems may be capable of performing diagnostic and therapeutic ultrasound simultaneously, their therapeutic ultrasound capabilities are designed primarily for, and therefore limited to, use in hyperthermia applications. None of these systems are suitable for carrying out ultrasonic imaging simultaneously with the ultrasonic rupture of vesicles for purposes such as enhanced cavitation or the targeted delivery of a bioactive agent to a region of a patient.
Accordingly, methods and apparatus for providing such a capability are needed. The present invention satisfies this need.
~ SUMMARY OF THE lNV~LlON
The present invention is directed to novel methods ~ and apparatus for performing diagnostic ultrasound simultaneously with the application of therapeutic ultrasonic waves to a region of a patient. In particular, CA 022207~6 1997-11-12 W O 96/39079 PCT~US96/07621 the methods and apparatus of the present invention are advantageous in performing ultrasonic imaging of a region of a patient while simultaneously applying therapeutic ultrasonic waves to the region in order to rupture vesicles a~m;n;~tered to that region for various purposes, such as, for example, the targeted release of a bioactive agent combined with the vesicles. The methods and apparatus of the present invention allow an operator to monitor the rupture of vesicles in real time.
According to one aspect of the present invention, an ultrasonic transducer assembly comprises a plurality of therapeutic transducer elements for generating therapeutic ultrasonic waves, and a plurality of diagnostic transducer elements for generating and/or receiving diagnostic ultrasonic waves. The therapeutic and diagnostic transducer elements are arranged on a common platform having a substantially planar upper surface. The plurality of therapeutic transducer elements are disposed on the planar surface of the platform centrally of the plurality of diagnostic transducer elements. Placement of the plurality of diagnostic transducer elements outwardly from the centrally located plurality of therapeutic transducer elements enlarges the field of view of the ultrasonic transducer assembly, increases the imaging sensitivity of the assembly and increases the resolution of images obtained using the ultrasonic transducer assembly.
The ultrasonic transducer assembly of the present invention is capable of performing diagnostic ultrasound in a region of a patient simultaneously with the application of therapeutic ultrasonic waves to that region. The ultrasonic transducer assembly of the present invention can be used in a wide variety of therapeutic applications, including hyperthermia, cavitation and the like. The ultrasonic transducer assembly of the present invention is particularly advantageous for carrying out ultrasonic imaging of vesicles administered to a region of a patient simultaneously with the application of therapeutic ultrasonic waves in order to CA 022207~6 1997-11-12 W O 96~9079 PCT/U~ 7621 rupture the vesicles for purposes, such as, for example, the targeted release of a bioactive agent combined with the vesicles.
Another aspect of the present invention relates to a method of carrying out ultrasonic imaging simultaneously with the ultrasonic rupture of vesicles in a region of a patient for purposes, such as, for example, enhanced cavitation or the targeted delivery of a bioactive agent combined with the vesicles. The method comprises the steps of (i) administering to the patient a quantity of vesicles;
(ii) insonating the vesicles in a region of the patient with therapeutic ultrasonic waves at a frequency and energy to cause the vesicles to rupture; and (iii) simultaneously receiving ultrasonic emissions from the insonated vesicles at a harmonic of the frequency of the therapeutic ultrasonic waves and generating an image of said region from the received ultrasonic emissions. Simultaneous imaging allows an operator to monitor the rupture of the vesicles in real time.
These and other features and advantages of the present invention will become evident hereinafter.
BRIEF DESCRIPTION OF THE DRAWINGS
The foregoing summary, as well as the following detailed description of the invention, is better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there is shown in the drawings embodiments that are presently preferred, it being understood, however, that the invention is not limited to the specific methods and instrumentalities disclosed. In the drawings:
Figure 1 is top view of a portion of an ultrasonic transducer assembly in accordance with one embodiment of the present invention;
Figure 2 is a cross-sectional view of the ultrasonic transducer assembly of Figure 1 taken along line 2-2 of Figure l;
CA 022207~6 1997-11-12 W O 96~9079 PCT/U',~'~7621 Figure 3 is a perspective view of the ultrasonic transducer assembly of Figure 2;
Figure 4 illustrates a second embodiment of an ultrasonic transducer assembly in accordance with the present invention;
Figure 5 shows a hand-held unit incorporating an ultrasonic transducer assembly of the present invention;
Figure 6 is a block diagram of apparatus for performing simultaneous diagnostic and therapeutic ultrasound using the ultrasonic transducer assembly of the present invention;
Figure 7 is a block diagram illustrating further details of the circuitry of Figure 6i Figure 8 illustrates a third embodiment of an ultrasonic transducer assembly in accordance with the present invention;
Figure 9 illustrates a fourth embodiment of an ultrasonic transducer assembly in accordance with the present invention;
Figures 10 (a) and (b) show a transesophageal probe incorporating an ultrasonic transducer assembly in accordance with the present invention;
Figures ll (a) and (b) show an intracavitary probe incorporating an ultrasonic transducer assembly in accordance with the present invention;
Figures 12 (a) and (b) show a second configuration of an intracavitary probe incorporating an ultrasonic transducer assembly in accordance with the present invention; and Figure 13 shows a third configuration of an intracavitary probe incorporating an ultrasonic transducer assembly in accordance with the present invention.
CA 022207~6 1997-11-12 W O 96~9079 ' PCT~US96/07621 DET~TT~n DESCRIPTION OF I~IE lNV~.l'ON
The present invention is directed to novel methods and apparatus for performing diagnostic ultrasound simultaneously with the application of therapeutic ultrasonic waves to a region of a patient. In particular, the methods and apparatus of the present invention are advantageous in performing ultrasonic imaging of a region of a patient while simultaneously applying therapeutic ultrasonic waves to the region for the purpose of rupturing vesicles administered to that region for various purposes, such as, for example, the targeted release of a bioactive agent into the region. The methods and apparatus of the present invention allow an operator to monitor the rupture of vesicles in real time.
As employed above and throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following m~n; ngs .
~ Lipid" refers to a synthetic or naturally-occurring amphipathic compound which comprises a hydrophilic component and a hydrophobic component. Lipids include, for example, fatty acids, neutral fats, phosphatides, glycolipids, aliphatic alcohols and waxes, terpenes and steroids.
"Lipid composition~ refers to a composition which comprises a lipid compound. Exemplary lipid compositions include suspensions, emulsions and vesicular compositions.
"Lipid formulation" refers to a composition which comprises a lipid compound and a bioactive agent.
~ Vesicle~ refers to a spherical entity which is characterized by the presence of an internal void.
Preferred vesicles are formulated from lipids, including the various lipids described herein. In any given vesicle, the lipids may be in the form of a monolayer or bilayer, and the mono- or bilayer lipids may be used to form one or more ~ 35 mono- or bilayers. In the case of more than one mono- or bilayer, the mono- or bilayers are generally concentric.
The lipid vesicles described herein include such entities CA 022207~6 1997-11-12 W O 96~9079 PCTrUS96/07621 commonly referred to as liposomes, micelles, bubbles, microbubbles, microspheres and the like. Thus, the lipids may be used to form a unilamellar vesicle (comprised of one monolayer or bilayer), an oligolamellar vesicle (comprised of about two or about three monolayers or bilayers) or a multilamellar vesicle (comprised of more than about three monolayers or bilayers). The internal void of the vesicles may be filled with a liquid, including, for example, an aqueous liquid, a gas, a gaseous precursor, and/or a solid or solute material, including, for example, a bioactive agent, as desired.
"Vesicular composition" refers to a composition which is formulated from lipids and which comprises vesicles.
"Vesicle formulation" refers to a composition which comprises vesicles and a bioactive agent.
"Liposome" refers to a generally spherical cluster or aggregate of amphipathic compounds, including lipid compounds, typically in the form of one or more concentric layers, for example, bilayers. They may also be referred to herein as lipid vesicles.
"Patient" refers to animals, including m~mm~l S, preferably humans.
"Bioactive agent" refers to a substance which ls used in connection with an application that is therapeutic or diagnostic in nature, such as in methods for diagnosing the presence or absence of a disease in a patient and/or in methods for the treatment of disease in a patient. As used herein, "bioactive agent'~ refers also to substances which are capable of exerting a biological effect in vitro and/or i~ vivo. The bioactive agents may be neutral or positively or negatively charged. Examples of suitable bioactive agents include diagnostic agents, pharmaceuticals, drugs, ,~
synthetic organic molecules, proteins, peptides, vitamins, steroids and genetic material, including nucleosides, nucleotides and polynucleotides.
CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 g "Diagnostic agent~ refers to any agent which is used in connection with methods for diagnosing the presence or absence of a disease in a patient. Exemplary diagnostic agents include, for example, contrast agents for use in 5 connection with ultrasound, magnetic resonance imaging or computed tomography of a patie~t, "Genetic materialn refers generally to nucleotides snd polynucleotide~, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The genetic material may be made by synthetic chemical methodology known to one of ordinary skill in the art, or by the use of recombinant technology, or by a combination of the two. The DNA and RNA
may optionally comprise llnn~t~ral nucleotides and may be single or double stranded. ~Genetic material" refers also to sense and anti-sense DNA and RNA, that is, a nucleotide sequence which is complementary to a specific sequence of nucleotides in DNA and/or RNA.
"Pharmaceutical" or ~drug~ refers to any therapeutic or prophylactic agent which is used in the treatment (including the prevention, diagnosis, alleviation, or cure) of a malady, affliction, disease or injury in a patient. Therapeutically useful peptides, polypeptides and polynucleotides are included within the me~n;ng of the term pharmaceutical or drug.
"Stabilizing material~ refers to a substance which is biocompatible and which i~ capable of promoting the formation of vesicles in a lipid composition. As used herein, ~stabilizing material" refers also to a substance which is biocompatible and which is capable of improving the stability of a vesicle. The stabilizing material may comprise a polymer. "Polymer", as used herein, refers to molecules formed from the chemical union of two or more repeating units. Accordingly, included within the term "polymer~ are, for example, dimers, trimers and oligomers.
The stabilizing material may also comprise a non-polymeric material, including, for example, monomeric molecules.
Encompassed also in the definition of ~stabilizing material"
CA 022207~6 1997-11-12 are certain of the present bioactive agents. The stabilizing material may be neutral or positively or negatively charged. Preferred among the neutral stabilizing materials are polar materials.
"Vesicle stability" refers to the ability of gas-filled vesicles to retain the gas entrapped therein after being exposed, for about one minute, to a pressure of about 300 mm Hg. Vesicle stability is measured in percent (~), this being the fraction of the amount of gas which is originally entrapped in the vesicle and which is retained after release of the pressure. Vesicle stability includes reference also to "vesicle resilience" which refers to the ability of a vesicle to return to its original size after release of the pressure.
"Viscosity" refers to the internal friction of a fluid that is measurable using st~n~rd viscosity-measuring means, such as a viscometer.
"Raising viscosity" refers to the increase of viscosity by greater than about 20~.
"Non-covalent association" refers to intermolecular interaction among two or more separate molecules, which interaction does not involve a covalent bond. Intermolecular interaction is dependent upon a variety of factors, including, for example, the polarity of the involved molecules, the charge (positive or negative), if any, of the involved molecules, and the like. Non-covalent associations are preferably selected ~rom the group consisting of ionic interaction, dipole-dipole interaction and van der Waal's forces and combinations thereof.
"Ionic interaction" refers to intermolecular interaction among two or more molecules, each of which is positively or negatively charged Thus, for example, ~'ionic interaction~ refers to the attraction between a first, positively charged molecule and a second, negatively charged molecule. Exemplary ionic interactions include, for example, the attraction between a negatively charged stabilizing material, for example, genetic material, and a CA 022207~6 1997-11-12 W O 96~9079 PCT/U~ v7621 positively charged lipid, for example, a cationic lipid, such as lauryltrimethylammonium bromide.
"Dipole-dipole interaction" refers generally to the attraction which can occur among two or more polar molecules. Thus, "dipole-dipole interaction" refers to the attraction of the positive end of a first polar molecule to the negative end of a second polar molecule. Dipole-dipole interactions are exemplified, for example, by the attraction between the electropositive head group, for example, the choline head group, of phosphatidylcholine and an electronegative atom, for example, a heteroatom, such as oxygen, nitrogen or sulphur, which is present in a stabilizing material, such as a polysaccharide. "Dipole-dipole interaction~ refers also to intermolecular hydrogen bonding in which a hydrogen atom serves as a bridge between electronegative atoms on separate molecules and in which a hydrogen atom is held to a first molecule by a covalent bond and to a second molecule by electrostatic forces.
"Van der Waal's forces" refers to the attractive forces between non-polar molecules that are accounted for by quantum mechanics. Van der Waal's forces are generally associated with momentary dipole moments which are induced by neighboring molecules and which involve changes in electron distribution.
Terms such as ~comprising a bioactive agent~ in combination with a bioactive agent," "combined with a bioactive agent" and the like, refer to the incorporation of a bioactive agent with a lipid composition. The bioactive agent can be combined with the lipid composition in any of a variety of ways. For example, when the lipid composition is in the form of a vesicular composition, the bioactive agent may be entrapped within the internal void of the vesicle.
The bioactive agent may also be integrated within the layer(s) or wall(s) o~ the vesicle, for example, by being interspersed among lipids which are contained within the vesicular layer(s) or wall(s). In addition, it is contemplated that the bioactive agent may be located on the CA 022207~6 1997-11-12 W O 96~9079 PCTrUS96/07621 surface of a vesicle. In this case, the bioactive agent may interact chemically with the surface of the vesicle and remain substantially adhered thereto. Such interaction may take the form of, for example, non-covalent association.
The interaction may result in the stabilization of the vesicle.
"Coat" or "coating" refers to the interaction of the stabilizing material with the lipid and/or vesicles and includes non-covalent interaction.
"Insonate" and variations thereof means to expose to ultrasonic waves.
Additional details concerning vesicles, vesicle compositions and vesicle formulations, including methods of producing the same, are provided in co-pending, commonly assigned, U.S. patent application Serial No. 08/417,238, filed April 5, 1995, entitled ~NOVEL COMPOSITIONS OF LIPIDS
AND STABILIZING MATERIALS", and in co-pending, commonly assigned, U.S. patent application Serial No. 08/076,250, filed June 11, 1993, entitled "NOVEL THERAPEUTIC DRUG
DELIVERY SYSTEMS", as well as their respective progeny, the disclosures of all of which are incorporated herein by reference in their entireties.
One aspect of the present invention is directed to an ultrasonic transducer assembly for performing diagnostic ultrasound in a region simultaneously with the application of therapeutic ultrasonic waves to the region. The ultrasonic transducer assembly of the present invention comprises a plurality of therapeutic transducer elements for generating therapeutic ultrasonic waves, and a plurality of diagnostic transducer elements for generating and/or receiving diagnostic ultrasonic waves. The therapeutic and diagnostic transducer elements are arranged on a common platform having a substantially planar upper surface. The plurality of therapeutic transducer elements are disposed on the planar surface of the platform centrally of the plurality of diagnostic transducer elements. Placement of the plurality of diagnostic transducer elements outwardly CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 from the centrally located plurality of therapeutic transducer elements enlarges the field of view of the ultrasonic transducer assembly, increases the imaging sensitivity of the assembly and increases the resolution of images obtained using the ultrasonic transducer assembly.
The ultrasonic transducer assembly of the present invention is capable of applying and receiving diagnostic ultrasonic waves to and from a region of a patient, simultaneously wit~ the application of therapeutic ultrasonic waves to that region. The ultrasonic transducer assembly of the present invention can be used in a wide variety of therapeutic applications, including hyperthermia, cavitation and the like. The ultrasonic transducer assembly of the present invention is particularly advantageous for carrying out ultrasonic imaging simultaneously with the ultrasonic rupture of vesicles for various purposes, such as, for example, ~nh~nced cavitation or the targeted release of bioa~ti-ve agen~s com~ined wi~h the vesicles. Wi~h ~he ultrasonic transducer assembly of the present invention, an operator can monitor the rupture of vesicles in real time.
Referring to the drawings wherein like numerals indicate like elements throughout, there is shown in Figure 1 a top view of a first embodiment of an ultrasonic transducer assembly 10 according to the present invention.
In accordance with this first embodiment, the plurality of therapeutic transducer elements comprises a linear array 16 of therapeutic transducer elements. AS used herein, the term "therapeutic transducer element" means a transducer element having acoustic properties suitable for generating ultrasonic waves at a frequency and energy useful in the practice of therapeutic ultrasound, and preferably having acoustic properties suitable for generating ultrasonic waves of a frequency and energy sufficient to rupture vesicles in vivo and/or in vitro. Preferably, the therapeutic transducer elements of the linear array 16 are capable of generating ultrasonic waves at a frequency in the range of about 0.25 to about 100 megahertz (MHz), more preferably in CA 022207~6 1997-11-12 W O 96/39079 PCT/U'5'1~7621 - 14 -the range of about 0.75 MHz to about 3.0 MHz, most preferably in the range of about 1.0 MHz to about 2.0 MHz.
The frequency at which a transducer element generates ultrasonic waves is, in part, a function of the thickness of the transducer element.
Further according to the first embodiment of the ultrasonic transducer assembly of the present invention, the second plurality of transducer elements comprises first and second linear arrays of diagnostic transducer elements 12 and 14, respectively, disposed on opposite sides of the linear array of therapeutic transducer elements 16. As used herein, the term "diagnostic transducer element" means a transducer element having acoustic properties suitable for generating and receiving acoustic signals in diagnostic ultrasound (imaging) applications, including those based on harmonic imaging techniques. Preferably, the diagnostic transducer elements of the first and second arrays 12, 14 are capable of generating and receiving ultrasonic waves at a frequency in the range of about 1.0 MHz to about 10.0 MHz.
Figure 2 is a cross-sectional view of the transducer assembly 10 of Figure 1, illustrating further details of the assembly 10 in accordance with the present embodiment. As shown, the respective linear arrays of transducer elements 12, 14, 16 are arranged on a common platform 18 having a substantially planar upper surface 18a.
In the present embodiment, a central portion of the upper surface 18a of the platform is stepped to accommodate the greater thickness of the linear array of therapeutic transducer elements 16. A first backing material 26 is disposed between the linear array of therapeutic transducer elements 16 and the upper surface 18a of the platform 18. A
second backing material 20 is disposed between each of the linear arrays of diagnostic transducer elements 12, 14 and the upper surface 18a of the platform. A common layer of an impedance matching material is provided on the opposite surfaces of each linear array of transducer elements 12, 14, 16, as shown.
CA 022207~6 1997-11-12 W O 96~9079 PCT/U~ 7621 The linear array of therapeutic transducer elements 16 can be operated in a continuous wave mode, or it can be operated in a pulse repetition frequency (PRF) mode selectable by an operator. The amount of energy supplied to the therapeutic transducer elements can be controlled by the operator, as can the depth of treatment. When employed as described below to rupture vesicles for therapeutic purposes, the linear array of therapeutic transducer elements 16 is preferably operated at energies in the range of 0. 05 to 5 ~ O W/cm2, and more preferably in the range of about 0.2 to about 2.5 W/cm2.
The first and second linear arrays of diagnostic transducer elements can be used to perform imaging tasks in a conventional manner and can be operated in several different modes. In one mode, each of the arrays 12, 14 is operated independently to create respective images on separate display screens simultaneously. In this mode, each linear array 12, 14 would transmit and receive its own ultrasonic waves. In another operating mode, one of the linear arrays 12, 14 can act as the transmitting array, and the other can act as the receiving array. The resultant image would be in the vicinity of the focal point of the array of therapeutic transducer elements 16. This modality would require conventional beam steering for proper focusing.
In a preferred imaging modality, described more fully below in connection with a novel method of the present invention, the linear array of therapeutic transducer elements 16 generates therapeutic ultrasonic waves having a frequency and energy sufficient to rupture a quantity of vesicles administered to a patient, and the two outer arrays of diagnostic transducer elements 12, 14 are used to receive ~ harmonic emissions from the insonated vesicles so that the vesicles can be imaged in real time as they rupture.
Preferably, the first and second arrays are used to receive second harmonic emissions from the insonated vesicles, i.e., emissions at twice the frequency of the incident, W O 96~9079 PCTAUS96/07621 therapeutic ultrasonic waves. However, receipt of emissionsat other harmonics of the incident waves, including both even and odd harmonics, can also be performed.
Both the therapeutic and diagnostic transducer elements are preferably formed of a ceramic piezoelectric material, such as, for example, lead zirconate titanate (PZT). Other piezoelectric materials can, however, be employed. As those skilled in the art know, the thickness and center-to-center spacing of adjacent transducer elements in a linear array determines the center, or resonant, frequency of the array. To achieve a desired center frequency, the thickness and center-to-center spacing of adjacent elements should be one-half the wavelength of an ultrasonic wave at that frequency. For example, for a desired center frequency of 3.5 MHz, the thickness and center-to-center spacing of adjacent transducer elements would be approximately 2.3xl0~2cm. The individual transducer elements of each array 12, 14, 16 can be formed in any conventional manner. For example, the transducer elements can be cut from a sheet of piezoelectric material using a diamond-bit saw, or alternatively, can be etched using a buffered solution of hydrofluoric acid (HF).
The first backing material 26 disposed between the linear array of therapeutic transducer elements 16 and the platform 18 preferably has an acoustic impedance suitable for the transmission of therapeutic ultrasonic waves. In the present embodiment, the first backing material preferably has an acoustic impedance in the range of about 2xl06 Kg/m2/s to about 3xl06 Kg/m2/s, which is suitable for transmission of therapeutic waves having frequencies and energies in the ranges set forth above. The first backing material may comprise any one of a variety of suitable materials. Preferably, the first backing material comprises a polymer matrix material that is bonded solidly to the linear array 16 of therapeutic transducer elements. For example, epoxy with tungsten powder can be used.
CA 022207~6 1997-11-12 W O 96/39079 PCTrUS96/07621 Alternatively, the first backing material 26 can comprise air.
The second backing material 20 disposed between each of the linear arrays of diagnostic transducer elements 12, 14 and the platform 18 preferably has an acoustic impedance suitable for the transmission and reception of diagnostic ultrasonic waves, preferably diagnostic ultrasonic waves having a fre~uency in the range of about 1.0 to about 10.0 MHz. Preferably, the second backing material has an acoustic impedance of about 7X106 Kg/m2/s.
The second backing material may comprise any one of a variety of suitable materials. Preferably, the second backing material comprises a polymer matrix material that is bonded solidly to the respective linear arrays 12, 14 of diagnostic transducer elements. For example, epoxy with tungsten powder may be used. Generally, the acoustic impedance of the first backing material 26 is lower than that of the second backing material 20.
The layer of matching material 24 preferably has an acoustic impedance that couples the mismatch of the acoustic impedance of the transducer elements to that of the biological tissue of the patient. Preferably, the matching material 24 has an acoustic impedance between that of the transducer elements and biological tissue. Any of a variety of suitable materials can be employed to form the matching layer 24, such as, for example, acrylic with epoxy.
Preferably, the therapeutic transducer elements 16 are isolated from the diagnostic transducer elements 12, 14 using a material that has a heavily damped acoustic impedance. Preferably, such a material would be located at areas 17 of the transducer assembly 10 of Figures 1 and 2.
An isolating material will reduce the acoustic interference , from the therapeutic transducer elements 16, which can add noise to the ultrasonic echos received by the diagnostic transducer elements 12, 14 during simultaneous imaging. A
variety of heavily damped materials can be employed as the isolating material, such as, for example, neoprene or air.
CA 022207~6 l997-ll-l2 W O 96~9079 PCTAUS96/07621 Figure 3 is a perspective view of the transducer assembly of Figure 2 illustrating the attachment of electrodes to the transducer elements of the respective linear arrays 12, 14, 16. Electrodes (not shown) on the top and bottom of each transducer element are connected to respective flexible circuit boards 28 and 30. The flexible circuit board 28 will connect one electrode on each transducer element to ground, and the other flexible circuit board 30 will connect the other electrode on each transducer element to an anode. Wire bonding or TA~3 bonding can be used to make the appropriate connections.
The number of elements in each linear array 12, 14, 16 is not limited to the number of elements illustrated in Figures 1 and 2. Figure 4 shows a second e~mbodiment of an ultrasonic transducer assembly 10' in accordance with the present invention. In this second embodiment, the ultrasonic transducer assembly has an increased number of elements in each linear array 12', 14', 16'. Increasing the number of transducer elements in each linear array 12, 14, 16 has the advantages of increased imaging resolution and higher therapeutic output.
Apodization techniques can be used with each linear array 12, 14, 16. Apodization will enhance contrast resolution and will eliminate side lobe artifacts in the linear arrays of diagnostic transducer elements 12, 14.
Apodization will also minimize side lobe artifacts in the linear array of therapeutic transducer elements 16.
Conventional beam steering techniques can be employed to focus the ultrasonic output of the linear array of therapeutic transducer elements 16, as well as to focus the linear arrays of diagnostic transducer elements 12, 14 in both transmit and receive modes. The m~; mllm angle for beam steering should be kept below 25 degrees to help minimize , grating lobes and side lobes that can affect image resolution.
Figure 5 shows a hand-held unit incorporating the ultrasonic transducer assembly 10 of the present invention.
CA 022207~6 1997-11-12 W O 96~9079 PCT/U',-1~7621 A housing 32 carries the transducer assembly 10 at one end.
A cable 36 connects the unit to an ultrasound system, described hereinafter in greater detail. A button 34 provides selective activation of the linear array of therapeutic transducer elements 16. The two arrays of diagnostic transducer elements 12, 14 can be used to locate a region to be treated. Once the desired region is located, the linear array of therapeutic transducer elements 16 can be activated by depressing the button 34.
The ultrasonic transducer assembly of the present invention, and the hand-held unit illustrated in Figure 5, are preferably constructed of non-magnetic materials that are compatible with magnetic resonance imaging (MRI) modalities. The contacts of the flexible circuits 28, 30 are preferably made of copper, or similar materials.
Housings are preferably made of non-magnetic materials such as stainless steel or a polymer material.
Figure 6 is a block diagram of an ultrasound system for use with the ultrasonic transducer assembly 10 of the present invention. A user interface 40 allows an operator to control various parameters, in a conventional manner, during both diagnostic and therapeutic operation of the transducer assembly 10. For example, the user can adjust the output energy of the transducer elements and can adjust the depth of focus of the emitted energy. A main system controller 42 controls the overall functioning of the ultrasound system, and can be implemented using a standard IBM PC/XT compatible board.
The main system controller 42 comm~n~.C a real time controller 44 to establish pulse train and timing parameters to achieve the desired diagnostic and therapeutic functions input by the operator. The real time controller 44 controls conventional focus modules 50, transmit/timing modules 52 and pulse/receiver modules 54 separately for the arrays of diagnostic and therapeutic transducer elements, e.g., linear arrays 12, 14 and 16. The focus modules 50, transmit/timing modules 52 and pulser/receiver modules 54 handle selection CA 022207~6 1997-11-12 W 096/39079 PCT~US96/07621 of the acoustic line of sight and focusing for both the diagnostic transducer arrays 12, 14 and the therapeutic transducer array 16. The transmit/timing modules 52 control the pulser/receiver modules 54 and enable the proper c~;3nnels to form appropriate apertures for both the diagnostic and therapeutic transducer arrays 12, 14, 16.
The pulser/receiver modules 54 generate the appropriate pulse trains for the individual transducer elements under control of the transmit/timing modules 52. Pulse width, duration, power, aperture size, and other parameter are controlled by the real time controller 44 in accordance with parameters input by the operator. For best imaging resolution, the ratio of focal distance to aperture size should be kept relatively low.
A high resolution monitor 48 provides the video display for the system. A video processor 45 serves as a selector and signal processor for acoustic echo information received by the diagnostic transducer arrays 12, 14. The video processor creates a single, analog stream of filtered, logarithmically compressed acoustic echo signals. Pre- and post-signal detection techniques, such as time gain compensation, are employed to compensate for attenuation versus penetration depth. A scan converter 46 converts the output of the video processor 45 into a signal compatible 2S with the monitor 48 to provide real-time display of two-~m~n~ional ultrasound images.
Figure 7 is a block diagram illustrating further details of the pulser/receiver modules 54 of Figure 6. A
pulser/receiver switch 56, which interfaces with the transmit/timing modules 52 and focus modules 50, controls the transmit and receive operations of the respective arrays of transducer elements 12, 14, 16. For a transmit operation, the pulser/receiver switch 56 sends signals to the appropriate pulser drivers 62, 64, 66. The pulser drivers 62, 64, 66 can be individually enabled via block 60.
Each transducer element of each array 12, 14, 16 is driven separately via respective element buses 74, 76, 78. The CA 022207~6 l997-ll-l2 W O 96~9079 PCTAUS96/07621 actual electrical signals are provided to the respective transducer elements by pulser circuits 68, 70 and 72. A
receiver multiplexer 80 controls the diagnostic transducer arrays 12, 14 in receive mode in order to "listen" for returned echos. When the diagnostic transducers 12, 14 are used in a transmit mode, the receiver multiplexer creates an open circuit to the receiver gain circuitry 82 so that the gain circuitry 82 does not get damaged.
RF filters 83 are employed to select a desired 10 frequency range for receiving returned echos via the diagnostic transducer elements 12, 14. An RF filter allows signals in a specified frequency range to pass while rejecting all other frequencies as noise. Because biological tissues act as a low-pass filter to incident 15 ultrasonic waves, when constructing an RF filter for maximum penetration, the RF filter should be designed with a center frequency that is below the center frequency of the diagnostic transducer elements.
Figure 8 illustrates a third embodiment of an 20 ultrasonic transducer assembly 84 in accordance with the present invention. In this third embodiment, the plurality of therapeutic transducer elements comprises a multiplexed phased array of therapeutic transducer elements 86, and the plurality of diagnostic transducer elements comprises a 25 multiplexed phased array of diagnostic transducer elements 88. As in the first and second embodiments, the array of therapeutic transducer elements 86 is disposed centrally of the array of diagnostic transducer elements on a common platform. Suitable backing and matching materials are 30 employed in the same manner as in the previous embodiments.
This embodiment can be used for treatment of areas close to the surface of a patient's skin.
Figure 9 illustrates a fourth embodiment of an ultrasonic transducer assembly 90 in accordance with the o 35 present invention. This fourth embodiment differs from the third embodiment in that the plurality of therapeutic transducer elements comprise an annular array of therapeutic CA 022207~6 1997-11-12 transducer elements 92. As in the previous embodiments, the annular array of therapeutic transducer elements 92 iS
disposed centrally of the array of diagnostic transducer elements 94 on a common platform. Suitable backing and matching materials are employed in the same manner as in the previous embodiments. This embodiment can be used for treatment close to the surface of a patient's skin and for treatment to medium depths.
As those skilled in the art can appreciate, the circuitry of Figures 6 and 7 must be modified in a conventional manner to operate with the multiplexed phased transducer arrays of the third and fourth embodiments.
In each of the foregoing embodiments, the therapeutic transducer elements are disposed centrally of the diagnostic transducer elements. Placing the diagnostic transducer elements outwardly from the centrally located therapeutic elements enlarges the field of view of the transducer assembly, increases the imaging sensitivity of the assembly and increases the resolution of images obtained using the transducer assembly.
The ultrasonic transducer assembly of the present invention can be incorporated into specialized ultrasonic probes to enable an operator to bring the transducer assembly closer to anatomical regions of interest. In this manner tissue differentiation can be more easily discerned, and an enhanced resolution and wider field of view can be achieved.
Figures 10 (a) and (b) show different views of a transesophageal probe 96 incorporating a transducer assembly in accordance with any one of the foregoing embodiments lO, 10', 84, 90 of the present invention. The transducer assembly is placed at the tip of the probe. The transesophageal probe can be used for imaging tissues and the heart from within the esophagus. The ultrasonic transducer assembly can be rotated manually through an angle of approximately 180 degrees. The transducer assembly can also be rotated in the anterior and posterior directions at CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 angles of up to 120 degrees. The transducer assembly can still further be moved/rotated to the left and right with an angle of rotation of up to 90 degrees.
Figures 11 (a) and (b) show different views of one configuration of an intracavitary probe 98 incorporating a transducer assembly in accordance any one of the embodiments 10, 10', 84, 90 described above. The intracavitary probe 98 of Figures 11 (a) and (b) can be used in endovaginal applications. As best shown in Figure 11, the platform of the transducer assembly can be contoured to suit the particular application.
Figures 12 (a) and (b) show different views of a second configuration of an intracavitary probe 100 incorporating a transducer assembly in accordance with any one of the foregoing embodiments. In this configuration, the transducer assembly is located at the extreme tip of the probe 100. Such a configuration can be used in endovaginal applications, or can be used for imaging the prostate.
Figure 13 shows a third configuration of an intracavitary probe 102 incorporating a transducer assembly in accordance with any one of the foregoing embodiments. In this configuration, the transducer assembly encircles the shaft of the probe just below the tip. This configuration can be used for either endovaginal or endorectal imaging.
According to another aspect of the present invention, a novel method is provided wherein ultrasonic imaging of vesicles in a region of a patient is carried out simultaneously with the application of therapeutic ultrasonic waves in order to rupture the vesicles for purposes, such as, for example, enhanced cavitation or the targeted release of a bioactive agent combined with the vesicles. The method comprises the steps of (i) administering to the patient a quantity of vesicles; (ii) insonating the vesicles in a region of the patient with therapeutic ultrasonic waves at a frequency and energy to cause the vesicles to rupture; and (iii) simultaneously receiving ultrasonic emissions from the insonated vesicles CA 022207~6 1997-11-12 W O 96/39079 PCT~US96/07621 at a harmonic of the frequency of the therapeutic ultrasonic waves and generating an image of said region from the received ultrasonic emissions. Simultaneous imaging allows an operator to monitor the rupture of the vesicles in real time.
As one skilled in the art would recognize once armed with the present disclosure, widely varying amounts of vesicles may be employed in the practice of the method of the present invention. As used herein, the term "quantity of vesicles" is intended to encompass all such amounts.
It is known that bubbles suspended in a liquid, such as the administered vesicles described herein, can be made to emit ultrasonic energy when exposed to ultrasonic waves. See, e.g., D.L. Miller, ~Ultrasonic Detection of Resonant Cavitation Bubbles in a Flow Tube by their Second Harmonic Emissions," Ultrasonics, pp. 217-224 (September 1981), the disclosure of which is hereby incorporated by reference. Emission of ultrasonic energy occurs at harmonics of the incident frequency. The method of the present invention takes advantage of this known property to allow an operator to image the vesicles of a vesicle formulation simultaneously with the application of therapeutic ultrasonic waves for the purpose of rupturing the vesicles. The therapeutic ultrasonic waves serve to produce the harmonic emissions in the vesicles prior to their rupture.
Emission at twice the frequency of the incident ultrasonic waves, called second harmonic emissions, are the strongest harmonic emissions at low amplitudes. Preferably, it is these so-called second harmonic emissions that are received in the aforementioned receiving step. It is desirable where possible to insonate the vesicles at a frequency which is close to optimal for eliciting maximal second harmonic signals, and this will vary depending upon the diameter, elasticity, and density of the vesicles. Of course, imaging can be performed at other harmonic frequencies, including both even and odd harmonic CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 frequencies, if desired. Imaging at harmonics and sub-harmonics of an excitation frequency is described in U.S.
Patent No. 5,410,516, the disclosure of which is hereby incorporated by reference in its entirety.
In order to achieve rupture of the vesicles, continuous wave therapeutic ultrasound is preferred, although the sound energy may be pulsed also. If pulsed sound energy is used, the sound will generally be pulsed in echo train lengths of about 8 to about 20 or more pulses at a time. Preferably, the echo train lengths are about 20 _ pulses at a time.
Energy levels of the therapeutic ultrasonic waves used to insonate the vesicles are preferably in the range of about 0.05 Watt (W) per square centimeter (cm2) to about 5.0 W/cm2, with energy levels of about 0.2 to about 2.5 W/cm2 being preferred. For very small vesicles, for example, vesicles having a diameter of less than about 0.5 micron, higher frequency ultrasonic waves are generally preferred.
This is because smaller vesicles are capable of absorbing ultrasonic energy more effectively at higher frequencies.
External application may be preferred for the skin and other superficial tissues, but for deep structures, the application of sonic energy via interstitial probes or intracavitary probes o~ the type described above may be preferred.
Experiments have shown that the onset of vesicle rupture occurs at the following spatial peak temporal average intensities (ISPTA)~ in milli-Watts (mW) per centimeter squared (cm2), for continuous-wave and selected duty cycles of ultrasonic waves. All values were obtained using a ultrasonic waves having a frequency of 1.0 MHz.
Duty Cycles ISPTA (mW/cm 5.3~ 290 10.4~ 100 21.9~ 70 CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 ¦¦ Continuous Wave ¦ 35 As these data reveal, rupture occurs most easily with continuous wave ultrasound.
Vesicles can be administered to the patient in a variety of forms adapted to the chosen route of administration, namely, parenterally, orally, or intraperitoneally. Parenteral administration, which is preferred, includes administration by the following routes:
intravenous; intramuscular; interstitially; intra-arterially; subcutaneous; intraocular; intrasynovial;transepithelial, including transdermal; pulmonary via inhalation; ophthalmic; sublingual and buccali topically, including ophthalmic; dermal; ocular; rectal; and nasal inhalation via insufflation. Intravenous administration is preferred among the routes of parenteral administration.
The useful dosage to be ~m; n; stered and the mode of administration will vary depending upon the age, weight, and type of ~n; m~l to be treated, and the particular therapeutic application intended. Typically, dosage is initiated at lower levels and increased until the desired therapeutic effect is achieved.
The patient may be any type of animal, but is preferably a vertebrate, more preferably a m~mm~l, and most preferably human. By region of a patient, it is meant the whole patient, or a particular area or portion of the patient.
The method of the present invention can also be carried out ln ~itro. For example, in cell culture applications, the vesicles may be added to the cells in cultures and then incubated. Therapeutic ultrasonic waves can then be applied to the culture media containing the cells and vesicles.
The method of the present invention is most advantageously carried out using the novel ultrasonic transducer assemblies of the present invention. For example, considering the ultrasonic transducer assembly 10 CA 022207~6 l997-ll-l2 W O 96/39079 PCTrUS96/07621 of Figure 1, the linear array of therapeutic transducer elements 16 can be used to perform the insonating step at a first frequency, such as 1.75 MHz, while the first and second linear arrays of diagnostic transducer elements 12, 14 can be fabricated and employed to receive the harmonic emissions of the vesicles at twice the incident frequency, i.e., 3.5 MHz.
EX~PLES
The method of the present invention is further described in the following prophetic examples. These prophetic examples are for illustrative purposes only, and are not to be construed as limiting the appended claims.
Exaunple 1 In a patient with a malignant soft tissue sarcoma of the thigh, 5.0 cubic centimeters (cc) of a vesicle formulation, 1.5X109 vesicles/milliliter (ml), combining 5 milligrams (mg) of doxorubicin is injected intravenously (IV). The patient~s tumor is ultrasonically imaged via a plurality of diagnostic transducer elements. As the vesicles pass through the tumor's microvasculature, they are detected via gray scale imaging and color Doppler. Upon detection, therapeutic ultrasonic waves are applied in bursts of 10 seconds using continuous wave ultrasound at a frequency of 1. 5 MHz and energy of o. 5 W/cm2 ~ The diagnostic transducer elements are employed to receive second harmonic emissions from the vesicles at a frequency of 3.0 MHz, twice the incident frequency of the therapeutic ultrasonic waves.
As the vesicles rupture, the doxorubicin is released locally within the tumor. Simultaneous imaging in accordance with the methods and apparatus of the present invention allows the physician to monitor the rupture of vesicles in real-time. High intra-tumoral concentrations o~ chemotherapy are attained, and the patient~s tumor is eradicated.
Exaunple 2 CA 022207~6 1997-11-12 W O 96~9079 PCTAUS96/07621 In a patient with breast cancer, 5.0 cc of a vesicle formulation comprising perfluoropentane vesicles labeled with antibodies to breast cancer epitopes is injected IV. Approximately 48 hours later, ultrasonic imaging of the patient's axilla is performed. A plurality of therapeutic transducer elements are employed to generate incident ultrasonic waves at a frequency insufficient to cause vesicle rupture, but sufficient to produce second harmonic emissions. Once second harmonic emissions are received from lymph nodes binding the antibody bearing vesicles, the energy of the therapeutic ultrasonic waves is increased to 5.0 W/cm2. The tumor bonded with vesicles lowers the cavitation threshold and local intra nodal cavitation is achieved destroying the malignant tumor.
Simultaneous imaging of the destruction is achieved via the plurality of diagnostic transducer elements.
Example 3 The same as example 2, except that the vesicles also contain 1.0 mg per ml of cis-platinum. A lower energy of 0.5 W/cm2 is applied to rupture the vesicles and release the cis-platinum within the lymph nodes, destroying the tumor.
Example 4 In a patient with myocardial ischemia involving the left anterior wall, 2.0 cc of cationic vesicles (1.0x109 vesicles/ml) binding the gene for endothelial growth factor (EFG) is injected IV. Continuous wave therapeutic ultrasound is applied in bursts at energies of between 0.05 and 0.2 W/cm2 to the le~t ventricular anterior wall myocardium. As the vesicles pass through the microvasculature of the anterior wall myocardial tissue, the vesicles are ruptured. Rupture o~ the vesicles not only releases the genes into the myocardium but also creates local shock waves which facilitate passage of the genetic material into the cardiac endothelial and myocyte cells.
W O 96/39079 PCT/U','/~7621 Local gene expression into EFG is achieved with resultant growth of new coronary circulation and improvement in coronary blood flow. Rupture of the vesicles is monitored in real time via the second harmonic emissions received by a plurality of diagnostic transducer elements.
Example 5 A patient with locally invasive esophageal cancer is treated with bubbles bearing mitomycin-C and the gene for BCL-2. An endoesophageal transducer, such as the probe lo illustrated in Figures lO(a) and (b), is placed in the esophagus and the position of the transducer is confirmed via the plurality of diagnostic transducer elements. A lO.o ml vesicle formulation binding drug and genetic material is then injected IV. As the vesicles pass through the tumor they are ruptured using bursts of O.S W/cm2 therapeutic ultrasonic waves. Rupture of the vesicles is monitored in real time. The therapy results in elimination of the tumor.
Example 6 As in example 5, except that the patient has pancreatic cancer. The transducer assembly is placed into the stomach and positioned such that imaging is performed through the posterior wall of the stomach. The pancreatic tumor is localized, the vesicle formulation is injected as in example 5, and therapy is performed while simultaneously imaging the rupture of the vesicles. The patient achieves a remission of pancreatic carcinoma.
Example 7 A patient with atherosclerosis is administered a 5.0 cc vesicle formulation having vesicles less than 1.0 micrometer (~m) in diameter, which are labeled with cholesterol. The vesicles accumulate in regions of lipid laden plaque. Transcutaneous therapeutic ultrasonic waves are then applied with an energy of 0.5 W/cm2. The vesicles CA 022207~6 1997-11-12 rupture as they lyse the plaque. Rupture of the vesicles is =
monitored in real-time.
Example 8 As in example 7, except that the vesicles are targeted to the atherosclerotic plaque by labeling with low density lipoproteins (LPL).
Example 9 As in example 7, except that the antisense construct to basic fibroblastic growth factor is applied to eliminate intimal hyperplasia and restenosis.
Example 10 As in examples 7 and 8, except that an endovascular catheter equipped with an ultrasonic transducer assembly is employed. The vesicles within the arterial plaque are then burst from within the vessel using the therapeutic transducer elements on the endovascular catheter.
Example 11 In a patient with prostate cancer, 10 ml of a vesicle formulation binding 10 mg of anti LHRH decapeptide are injected IV. An endorectal probe with an ultrasonic transducer assembly of the present invention is placed within the rectum and positioned adjacent the prostate gland with the aid of the diagnostic transducer elements. As the vesicles are detected coursing within the microvasculature of the prostatic tumor, high energy therapeutic ultrasonic waves are applied, and the vesicles are ruptured, releasing high local concentrations of the inhibitory peptide.
Simultaneous imaging of the vesicles is performed via second harmonic emissions. Tumor regression is thus achieved ~rom an outpatient, minimally invasive procedure.
The disclosures of each patent, patent applicationand publication cited or described in this document are hereby incorporated by reference, in their entirety.
As the foregoing illustrates, the present invention is directed to novel methods and apparatus for performing diagnostic ultrasound simultaneously with the application of therapeutic ultrasonic waves to a region of a patient. In particular, the methods and apparatus o~ the present invention are advantageous in performing ultrasonic imaging of a region of a patient while simultaneously applying therapeutic ultrasonic waves to the region in order to rupture vesicles in the region for therapeutic purposes, such as, for example, the targeted release of a bioactive agent. The methods and apparatus of the present invention allow an operator to monitor the rupture of vesicles in real time. It is understood that changes may be made to the embodiments described above without departing from the broad inventive concepts thereof. Accordingly, the present invention is not limited to the particular embodiments disclosed, but is intended to cover all modifications that are within the spirit and scope of the invention as defined by the appended claims.
Claims (27)
1. An ultrasonic transducer assembly for simultaneous application of diagnostic and therapeutic ultrasonic waves comprising:
a plurality of therapeutic transducer elements for generating therapeutic ultrasonic waves;
a plurality of diagnostic transducer elements for generating and receiving diagnostic ultrasonic waves; and a platform having a substantially planar upper surface on which said pluralities of therapeutic and diagnostic transducer elements are arranged, said plurality of therapeutic transducer elements being disposed on said planar surface centrally of said plurality of diagnostic transducer elements.
a plurality of therapeutic transducer elements for generating therapeutic ultrasonic waves;
a plurality of diagnostic transducer elements for generating and receiving diagnostic ultrasonic waves; and a platform having a substantially planar upper surface on which said pluralities of therapeutic and diagnostic transducer elements are arranged, said plurality of therapeutic transducer elements being disposed on said planar surface centrally of said plurality of diagnostic transducer elements.
2. The ultrasonic transducer assembly of claim 1 further comprising a first backing material disposed between said plurality of therapeutic transducer elements and the planar surface of said platform, and a second backing material disposed between said plurality of diagnostic transducer elements and the planar surface of said platform.
3. The ultrasonic transducer assembly of claim 2 wherein said first backing material has a lower acoustic impedance than said second backing material.
4. The ultrasonic transducer assembly of claim 2 wherein said first backing material has an acoustic impedance in the range of about 2x10 6 Kg/m2/s to 3X10 6 Kg/m2/s.
5. The ultrasonic transducer assembly of claim 2 wherein said second backing material has an acoustic impedance of about 7X10 6 Kg/m2/s.
6. The ultrasonic transducer assembly of claim 2 wherein said first and second backing materials are each formed of a polymer matrix material.
7. The ultrasonic transducer assembly of claim 2 wherein said first backing material comprises one of an epoxy with tungsten powder and air.
8. The ultrasonic transducer assembly of claim 2 wherein said second backing material comprises an epoxy with tungsten powder.
9. The ultrasonic transducer assembly of claim 1 wherein said plurality of therapeutic transducer elements are isolated from said plurality of diagnostic transducer elements on said planar surface by a material having a heavily damped acoustic impedance.
10. The ultrasonic transducer assembly of claim 9 wherein said acoustic insulating material comprises one of neoprene and air.
11. The ultrasonic transducer assembly of claim 1 wherein said plurality of therapeutic transducer elements comprises a linear array of therapeutic transducer elements, and wherein said plurality of diagnostic transducer elements comprises first and second linear arrays of diagnostic transducer elements disposed on opposite sides of said linear array of therapeutic transducer elements.
12. The ultrasonic transducer assembly of claim 1 wherein said plurality of therapeutic transducer elements comprises a multiplexed phased array of therapeutic transducer elements, and said plurality of diagnostic transducer elements comprises a multiplexed phased array of diagnostic transducer elements that surround the multiplexed phased array of therapeutic transducer elements on said planar surface.
13. The ultrasonic transducer assembly of claim 1 wherein said plurality of therapeutic transducer elements comprises an annular array of therapeutic transducer elements, and said plurality of diagnostic transducer elements comprises a multiplexed phased array of diagnostic transducer elements that surround the annular array of therapeutic transducer elements on said planar surface.
14. The ultrasonic transducer assembly of claim 1 further comprising a layer of an impedance matching material disposed in facing relation over said therapeutic and diagnostic transducer elements on a side opposite said platform.
15. A method for treating a patient comprising the steps of:
(i) administering to the patient a quantity of vesicles;
(ii) insonating the vesicles in a region of the patient with therapeutic ultrasonic waves at a frequency and energy to cause the vesicles to rupture; and (iii) simultaneously receiving ultrasonic emissions from the insonated vesicles at a harmonic of the frequency of the therapeutic ultrasonic waves and generating an image of said region from the received ultrasonic emissions.
(i) administering to the patient a quantity of vesicles;
(ii) insonating the vesicles in a region of the patient with therapeutic ultrasonic waves at a frequency and energy to cause the vesicles to rupture; and (iii) simultaneously receiving ultrasonic emissions from the insonated vesicles at a harmonic of the frequency of the therapeutic ultrasonic waves and generating an image of said region from the received ultrasonic emissions.
16. The method recited in claim 15 wherein the therapeutic ultrasonic waves comprise continuous-wave ultrasonic signals.
17. The method recited in claim 15 wherein the therapeutic ultrasonic waves are pulsed.
18. The method recited in claim 15 wherein the harmonic at which the ultrasonic emissions of said vesicles are received comprises a second harmonic of the frequency of said therapeutic ultrasonic waves.
19. The method recited in claim 15 wherein said image is generated in real-time.
20. The method recited in claim 15 further comprising the step of monitoring the vesicles using diagnostic ultrasonic waves to determined the presence of the vesicles in said region prior to said insonating step.
21. The method recited in claim 15 wherein the vesicles are administered intravenously.
22. The method recited in claim 15 wherein the vesicles are combined with a bioactive agent to form a vesicle formulation, rupture of the vesicles causing release of the bioactive agent into the region.
23. The method recited in claim 15 wherein said insonating step is performed using a plurality of therapeutic transducer elements, and said receiving step is performed simultaneously using a plurality of diagnostic transducer elements, wherein the plurality of therapeutic transducer elements are located centrally of the plurality of diagnostic transducer elements on a common platform.
24. The method recited in claim 15 wherein the frequency of the therapeutic ultrasonic waves is in the range of about 0.75 to about 3.0 MHz.
25. The method recited in claim 24 wherein the frequency of the therapeutic ultrasonic waves is in the range of about 1.0 to about 2.0 MHz.
26. The method recited in claim 15 wherein the energy of said therapeutic ultrasonic waves is in the range of about 0.05 W/cm2 to about 5.0 W/cm2.
27. The method recited in claim 26 wherein the energy of said therapeutic ultrasonic waves is in the range of about 0.2 W/cm2 to about 2.5 W/cm2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/468,052 US5558092A (en) | 1995-06-06 | 1995-06-06 | Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously |
US08/468,052 | 1995-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2220756A1 true CA2220756A1 (en) | 1996-12-12 |
Family
ID=23858255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002220756A Abandoned CA2220756A1 (en) | 1995-06-06 | 1996-05-24 | Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously |
Country Status (7)
Country | Link |
---|---|
US (1) | US5558092A (en) |
EP (1) | EP0836420A4 (en) |
JP (2) | JPH11506636A (en) |
CN (1) | CN1186420A (en) |
AU (1) | AU711788B2 (en) |
CA (1) | CA2220756A1 (en) |
WO (1) | WO1996039079A1 (en) |
Families Citing this family (430)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3829999A1 (en) | 1988-09-01 | 1990-03-15 | Schering Ag | ULTRASONIC METHOD AND CIRCUITS THEREOF |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US5656211A (en) | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
DE69215722T3 (en) * | 1991-03-22 | 2001-03-08 | Katsuro Tachibana | Amplifiers for ultrasound therapy of diseases and liquid pharmaceutical compositions containing them |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US6285898B1 (en) | 1993-07-20 | 2001-09-04 | Biosense, Inc. | Cardiac electromechanics |
US6983179B2 (en) | 1993-07-20 | 2006-01-03 | Biosense, Inc. | Method for mapping a heart using catheters having ultrasonic position sensors |
US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
DE4443947B4 (en) * | 1994-01-14 | 2005-09-22 | Siemens Ag | endoscope |
WO1998053855A1 (en) | 1997-05-30 | 1998-12-03 | Alliance Pharmaceutical Corp. | Methods and apparatus for monitoring and quantifying the movement of fluid |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
WO1996022111A1 (en) * | 1995-01-19 | 1996-07-25 | Sound Science Limited Partnership | Local delivery and monitoring of drugs |
USRE38971E1 (en) | 1995-01-31 | 2006-02-07 | Kabushiki Kaisha Toshiba | Ultrasound diagnostic apparatus and method |
US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US6009046A (en) * | 1995-03-02 | 1999-12-28 | Acuson Corporation | Ultrasonic harmonic imaging system and method |
US6104670A (en) * | 1995-03-02 | 2000-08-15 | Acuson Corporation | Ultrasonic harmonic imaging system and method |
US6027448A (en) * | 1995-03-02 | 2000-02-22 | Acuson Corporation | Ultrasonic transducer and method for harmonic imaging |
US6005827A (en) * | 1995-03-02 | 1999-12-21 | Acuson Corporation | Ultrasonic harmonic imaging system and method |
US5608690A (en) * | 1995-03-02 | 1997-03-04 | Acuson Corporation | Transmit beamformer with frequency dependent focus |
DE69634714T2 (en) * | 1995-03-31 | 2006-01-19 | Kabushiki Kaisha Toshiba, Kawasaki | Therapeutic ultrasound device |
US6334846B1 (en) * | 1995-03-31 | 2002-01-01 | Kabushiki Kaisha Toshiba | Ultrasound therapeutic apparatus |
US5997898A (en) | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
DE19644314A1 (en) * | 1995-11-23 | 1997-05-28 | Siemens Ag | Therapy appts. with acoustic wave source |
US6915149B2 (en) | 1996-01-08 | 2005-07-05 | Biosense, Inc. | Method of pacing a heart using implantable device |
DE69733249T8 (en) | 1996-02-15 | 2006-04-27 | Biosense Webster, Inc., Diamond Bar | DETERMINATION OF THE EXACT POSITION OF ENDOSCOPES |
US6618612B1 (en) | 1996-02-15 | 2003-09-09 | Biosense, Inc. | Independently positionable transducers for location system |
CA2246284C (en) | 1996-02-15 | 2008-01-29 | Biosense, Inc. | Catheter with lumen |
EP0888086B1 (en) | 1996-02-15 | 2005-07-27 | Biosense Webster, Inc. | Excavation probe |
JP3881028B2 (en) | 1996-02-15 | 2007-02-14 | バイオセンス・インコーポレイテッド | Movable transmit or receive coils for position detection systems |
EP0910300B1 (en) | 1996-02-15 | 2003-12-03 | Biosense, Inc. | Site marking probe |
WO1997029678A2 (en) | 1996-02-15 | 1997-08-21 | Biosense Inc. | Catheter calibration and usage monitoring system |
US6453190B1 (en) | 1996-02-15 | 2002-09-17 | Biosense, Inc. | Medical probes with field transducers |
AU704129B2 (en) | 1996-02-27 | 1999-04-15 | Biosense, Inc. | Location system with field actuation sequences |
DE69736549T2 (en) | 1996-02-29 | 2007-08-23 | Acuson Corp., Mountain View | SYSTEM, METHOD AND CONVERTER FOR ORIENTING MULTIPLE ULTRASOUND IMAGES |
WO1997040679A1 (en) * | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
BE1010407A4 (en) * | 1996-07-04 | 1998-07-07 | Undatim Ultrasonics | Method and installation of water treatment. |
US5846202A (en) * | 1996-07-30 | 1998-12-08 | Acuson Corporation | Ultrasound method and system for imaging |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
CA2263568C (en) | 1996-09-11 | 2008-12-02 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a contrast agent and a renal vasodilator |
US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
US5769790A (en) * | 1996-10-25 | 1998-06-23 | General Electric Company | Focused ultrasound surgery system guided by ultrasound imaging |
EP0841576B1 (en) * | 1996-11-12 | 2004-04-07 | Philips Medical Systems (Cleveland), Inc. | Nuclear magnetic resonance apparatus |
US6030344A (en) * | 1996-12-04 | 2000-02-29 | Acuson Corporation | Methods and apparatus for ultrasound image quantification |
GB2321853A (en) | 1997-02-08 | 1998-08-12 | Intravascular Res Ltd | Ultrasound Emitting Stent |
US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6110120A (en) | 1997-04-11 | 2000-08-29 | Acuson Corporation | Gated ultrasound imaging apparatus and method |
US6582392B1 (en) * | 1998-05-01 | 2003-06-24 | Ekos Corporation | Ultrasound assembly for use with a catheter |
US6723063B1 (en) | 1998-06-29 | 2004-04-20 | Ekos Corporation | Sheath for use with an ultrasound element |
US6676626B1 (en) | 1998-05-01 | 2004-01-13 | Ekos Corporation | Ultrasound assembly with increased efficacy |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
US6050944A (en) * | 1997-06-17 | 2000-04-18 | Acuson Corporation | Method and apparatus for frequency control of an ultrasound system |
ES2129364B1 (en) * | 1997-06-20 | 2000-01-16 | Medicina En Forma S L | A TEAM FOR THE TREATMENT OF CAPSULAR CONTRACTS IN BREAST FACILITIES AND ITS APPLICATION PROCEDURE. |
US5810888A (en) * | 1997-06-26 | 1998-09-22 | Massachusetts Institute Of Technology | Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery |
US6193659B1 (en) | 1997-07-15 | 2001-02-27 | Acuson Corporation | Medical ultrasonic diagnostic imaging method and apparatus |
US5913823A (en) * | 1997-07-15 | 1999-06-22 | Acuson Corporation | Ultrasound imaging method and system for transmit signal generation for an ultrasonic imaging system capable of harmonic imaging |
US5833614A (en) * | 1997-07-15 | 1998-11-10 | Acuson Corporation | Ultrasonic imaging method and apparatus for generating pulse width modulated waveforms with reduced harmonic response |
US6132374A (en) * | 1997-08-01 | 2000-10-17 | Acuson Corporation | Ultrasonic imaging method and system |
US6023977A (en) | 1997-08-01 | 2000-02-15 | Acuson Corporation | Ultrasonic imaging aberration correction system and method |
US6312379B1 (en) | 1997-08-15 | 2001-11-06 | Acuson Corporation | Ultrasonic harmonic imaging system and method using waveform pre-distortion |
US5944666A (en) * | 1997-08-21 | 1999-08-31 | Acuson Corporation | Ultrasonic method for imaging blood flow including disruption or activation of contrast agent |
US6106465A (en) * | 1997-08-22 | 2000-08-22 | Acuson Corporation | Ultrasonic method and system for boundary detection of an object of interest in an ultrasound image |
US5873830A (en) * | 1997-08-22 | 1999-02-23 | Acuson Corporation | Ultrasound imaging system and method for improving resolution and operation |
US5928151A (en) * | 1997-08-22 | 1999-07-27 | Acuson Corporation | Ultrasonic system and method for harmonic imaging in three dimensions |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
US6049159A (en) * | 1997-10-06 | 2000-04-11 | Albatros Technologies, Inc. | Wideband acoustic transducer |
US5860931A (en) * | 1997-10-10 | 1999-01-19 | Acuson Corporation | Ultrasound method and system for measuring perfusion |
US5935069A (en) * | 1997-10-10 | 1999-08-10 | Acuson Corporation | Ultrasound system and method for variable transmission of ultrasonic signals |
US6623430B1 (en) | 1997-10-14 | 2003-09-23 | Guided Therapy Systems, Inc. | Method and apparatus for safety delivering medicants to a region of tissue using imaging, therapy and temperature monitoring ultrasonic system |
US6050943A (en) * | 1997-10-14 | 2000-04-18 | Guided Therapy Systems, Inc. | Imaging, therapy, and temperature monitoring ultrasonic system |
US20020055731A1 (en) * | 1997-10-24 | 2002-05-09 | Anthony Atala | Methods for promoting cell transfection in vivo |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US5897500A (en) * | 1997-12-18 | 1999-04-27 | Acuson Corporation | Ultrasonic imaging system and method for displaying composite fundamental and harmonic images |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
US6077225A (en) * | 1998-01-23 | 2000-06-20 | Hewlett-Packard Company | Ultrasound method for enhancing image presentation when contrast agents are used |
US6120454A (en) * | 1998-02-03 | 2000-09-19 | Boston Scientific Corporation | Annular array ultrasound catheter |
US6017312A (en) * | 1998-02-03 | 2000-01-25 | Boston Scientific Corporation | Multi-channel rotary transformer |
US6344037B1 (en) | 1998-02-03 | 2002-02-05 | Scimed Life Systems, Inc. | Integrated coaxial transmission line and flexible drive cable |
ES2335826T3 (en) * | 1998-02-05 | 2010-04-05 | Miwa Science Laboratory Inc. | ULTRASONIC WAVES IRRADIATION DEVICE AND NON-THERAPEUTIC TREATMENT PROCEDURE. |
US20020055702A1 (en) * | 1998-02-10 | 2002-05-09 | Anthony Atala | Ultrasound-mediated drug delivery |
US6385474B1 (en) | 1999-03-19 | 2002-05-07 | Barbara Ann Karmanos Cancer Institute | Method and apparatus for high-resolution detection and characterization of medical pathologies |
US5957852A (en) * | 1998-06-02 | 1999-09-28 | Acuson Corporation | Ultrasonic harmonic imaging system and method |
US20030078227A1 (en) * | 1998-07-02 | 2003-04-24 | Greenleaf James F. | Site-directed transfection with ultrasound and cavitation nuclei |
US6042556A (en) * | 1998-09-04 | 2000-03-28 | University Of Washington | Method for determining phase advancement of transducer elements in high intensity focused ultrasound |
US5961464A (en) * | 1998-09-16 | 1999-10-05 | Hewlett-Packard Company | Ultrasound contrast agent detection using spectral analysis from acoustic scan lines |
US7722539B2 (en) * | 1998-09-18 | 2010-05-25 | University Of Washington | Treatment of unwanted tissue by the selective destruction of vasculature providing nutrients to the tissue |
US6425867B1 (en) | 1998-09-18 | 2002-07-30 | University Of Washington | Noise-free real time ultrasonic imaging of a treatment site undergoing high intensity focused ultrasound therapy |
US7686763B2 (en) * | 1998-09-18 | 2010-03-30 | University Of Washington | Use of contrast agents to increase the effectiveness of high intensity focused ultrasound therapy |
US6048316A (en) * | 1998-10-16 | 2000-04-11 | Acuson Corporation | Medical diagnostic ultrasonic imaging system and method for displaying composite fundamental and harmonic images |
WO2000030554A1 (en) | 1998-11-20 | 2000-06-02 | Jones Joie P | Methods for selectively dissolving and removing materials using ultra-high frequency ultrasound |
US6309355B1 (en) | 1998-12-22 | 2001-10-30 | The Regents Of The University Of Michigan | Method and assembly for performing ultrasound surgery using cavitation |
US6444192B1 (en) | 1999-02-05 | 2002-09-03 | The Regents Of The University Of California | Diagnostic imaging of lymph structures |
US7549960B2 (en) * | 1999-03-11 | 2009-06-23 | Biosense, Inc. | Implantable and insertable passive tags |
US7575550B1 (en) | 1999-03-11 | 2009-08-18 | Biosense, Inc. | Position sensing based on ultrasound emission |
US7590441B2 (en) * | 1999-03-11 | 2009-09-15 | Biosense, Inc. | Invasive medical device with position sensing and display |
US7174201B2 (en) * | 1999-03-11 | 2007-02-06 | Biosense, Inc. | Position sensing system with integral location pad and position display |
US7558616B2 (en) * | 1999-03-11 | 2009-07-07 | Biosense, Inc. | Guidance of invasive medical procedures using implantable tags |
FR2791249B1 (en) * | 1999-03-25 | 2001-06-15 | Edap Technomed | COUPLING MEDIUM FOR POWER ULTRASOUND |
US6488626B1 (en) * | 1999-04-07 | 2002-12-03 | Riverside Research Institute | Ultrasonic sensing by induced tissue motion |
US6398792B1 (en) * | 1999-06-21 | 2002-06-04 | O'connor Lawrence | Angioplasty catheter with transducer using balloon for focusing of ultrasonic energy and method for use |
US6740039B1 (en) | 1999-08-20 | 2004-05-25 | Koninklijke Philips Electronics N.V. | Methods and apparatus for displaying information relating to delivery and activation of a therapeutic agent using ultrasound energy |
US6527718B1 (en) | 1999-08-20 | 2003-03-04 | Brian G Connor | Ultrasound system for continuous imaging and delivery of an encapsulated agent |
US6406429B1 (en) * | 1999-08-23 | 2002-06-18 | City Of Hope | Detection of cystic structures using pulsed ultrasonically induced resonant cavitation |
US7520856B2 (en) * | 1999-09-17 | 2009-04-21 | University Of Washington | Image guided high intensity focused ultrasound device for therapy in obstetrics and gynecology |
US7510536B2 (en) | 1999-09-17 | 2009-03-31 | University Of Washington | Ultrasound guided high intensity focused ultrasound treatment of nerves |
US20050240170A1 (en) * | 1999-10-25 | 2005-10-27 | Therus Corporation | Insertable ultrasound probes, systems, and methods for thermal therapy |
CA2387127A1 (en) | 1999-10-25 | 2001-05-17 | Therus Corporation | Use of focused ultrasound for vascular sealing |
US6626855B1 (en) * | 1999-11-26 | 2003-09-30 | Therus Corpoation | Controlled high efficiency lesion formation using high intensity ultrasound |
AU2598201A (en) * | 1999-12-23 | 2001-07-03 | Therus Corporation | Ultrasound transducers for imaging and therapy |
US6635017B1 (en) * | 2000-02-09 | 2003-10-21 | Spentech, Inc. | Method and apparatus combining diagnostic ultrasound with therapeutic ultrasound to enhance thrombolysis |
US6428477B1 (en) * | 2000-03-10 | 2002-08-06 | Koninklijke Philips Electronics, N.V. | Delivery of theraputic ultrasound by two dimensional ultrasound array |
US6613004B1 (en) * | 2000-04-21 | 2003-09-02 | Insightec-Txsonics, Ltd. | Systems and methods for creating longer necrosed volumes using a phased array focused ultrasound system |
CA2312142A1 (en) * | 2000-06-22 | 2001-12-22 | An-Go-Gen Inc. | Injection system for gene delivery |
JP4454114B2 (en) * | 2000-06-30 | 2010-04-21 | 株式会社日立メディコ | Ultrasonic therapy device |
US6425869B1 (en) | 2000-07-18 | 2002-07-30 | Koninklijke Philips Electronics, N.V. | Wideband phased-array transducer for uniform harmonic imaging, contrast agent detection, and destruction |
KR20040015011A (en) | 2000-09-29 | 2004-02-18 | 뉴 헬스 사이언시즈 인코포레이티드 | Systems and methods for assessing vascular health |
US7104958B2 (en) * | 2001-10-01 | 2006-09-12 | New Health Sciences, Inc. | Systems and methods for investigating intracranial pressure |
US6955648B2 (en) * | 2000-09-29 | 2005-10-18 | New Health Sciences, Inc. | Precision brain blood flow assessment remotely in real time using nanotechnology ultrasound |
US7914453B2 (en) | 2000-12-28 | 2011-03-29 | Ardent Sound, Inc. | Visual imaging system for ultrasonic probe |
JP4712980B2 (en) * | 2001-01-18 | 2011-06-29 | 株式会社日立メディコ | Ultrasonic device |
JP2002209905A (en) * | 2001-01-22 | 2002-07-30 | Hitachi Medical Corp | Ultrasonic therapy probe and ultrasonic therapy apparatus |
US7846096B2 (en) | 2001-05-29 | 2010-12-07 | Ethicon Endo-Surgery, Inc. | Method for monitoring of medical treatment using pulse-echo ultrasound |
US20030032898A1 (en) | 2001-05-29 | 2003-02-13 | Inder Raj. S. Makin | Method for aiming ultrasound for medical treatment |
US6537224B2 (en) | 2001-06-08 | 2003-03-25 | Vermon | Multi-purpose ultrasonic slotted array transducer |
JP4426288B2 (en) * | 2001-07-10 | 2010-03-03 | ソノジーン,リミテッド ライアビリティー カンパニー | Enhanced transfection of liver DNA |
JP4157688B2 (en) * | 2001-09-20 | 2008-10-01 | 株式会社日立メディコ | Ultrasonic diagnostic equipment |
CN1157239C (en) | 2001-11-05 | 2004-07-14 | 北京源德生物医学工程股份有限公司 | Conducting medium contained structure for ultrasonic source of high-energy focusing ultrasonic treating apparatus |
US20070255169A1 (en) * | 2001-11-19 | 2007-11-01 | Dune Medical Devices Ltd. | Clean margin assessment tool |
US7505811B2 (en) | 2001-11-19 | 2009-03-17 | Dune Medical Devices Ltd. | Method and apparatus for examining tissue for predefined target cells, particularly cancerous cells, and a probe useful in such method and apparatus |
CN1160136C (en) * | 2001-11-28 | 2004-08-04 | 北京源德生物医学工程股份有限公司 | Ultrasonic wave heat therapeutic apparatus and focus temp. pre-measuring method |
AU2002359576A1 (en) | 2001-12-03 | 2003-06-17 | Ekos Corporation | Catheter with multiple ultrasound radiating members |
JP4167178B2 (en) * | 2001-12-14 | 2008-10-15 | イコス コーポレイション | Determination of resumption of blood flow |
US8019411B2 (en) * | 2002-01-04 | 2011-09-13 | Dune Medical Devices Ltd. | Probes, systems, and methods for examining tissue according to the dielectric properties thereof |
US7720532B2 (en) | 2004-03-23 | 2010-05-18 | Dune Medical Ltd. | Clean margin assessment tool |
US8721565B2 (en) | 2005-08-04 | 2014-05-13 | Dune Medical Devices Ltd. | Device for forming an effective sensor-to-tissue contact |
US8116845B2 (en) | 2005-08-04 | 2012-02-14 | Dune Medical Devices Ltd. | Tissue-characterization probe with effective sensor-to-tissue contact |
US7809425B2 (en) * | 2003-07-24 | 2010-10-05 | Dune Medical Devices Ltd. | Method and apparatus for examining a substance, particularly tissue, to characterize its type |
US8032211B2 (en) * | 2002-01-04 | 2011-10-04 | Dune Medical Devices Ltd. | Probes, systems, and methods for examining tissue according to the dielectric properties thereof |
US20030163190A1 (en) * | 2002-02-25 | 2003-08-28 | Scimed Life Systems, Inc. | High temperature stent delivery system |
US8226629B1 (en) | 2002-04-01 | 2012-07-24 | Ekos Corporation | Ultrasonic catheter power control |
US6716168B2 (en) * | 2002-04-30 | 2004-04-06 | Siemens Medical Solutions Usa, Inc. | Ultrasound drug delivery enhancement and imaging systems and methods |
US7285092B2 (en) | 2002-12-18 | 2007-10-23 | Barbara Ann Karmanos Cancer Institute | Computerized ultrasound risk evaluation system |
EP1551303A4 (en) | 2002-05-16 | 2009-03-18 | Karmanos B A Cancer Inst | Method and system for combined diagnostic and therapeutic ultrasound system incorporating noninvasive thermometry, ablation control and automation |
WO2004004572A1 (en) * | 2002-07-08 | 2004-01-15 | Prorhythm, Inc. | Cardiac ablation using microbubbles |
US6921371B2 (en) | 2002-10-14 | 2005-07-26 | Ekos Corporation | Ultrasound radiating members for catheter |
ES2279178T3 (en) * | 2002-11-04 | 2007-08-16 | Ashland Licensing And Intellectual Property Llc | DEVICE AND PROCEDURE FOR THE TREATMENT OF A LIQUID LIQUID BY ULTRASOUND IN THE PREVENTION OF THE GROWTH OF HYPERPROLIFERATIVE OR INFECTED CELLS. |
US6824518B2 (en) * | 2002-11-26 | 2004-11-30 | Siemens Medical Solutions Usa, Inc. | High transmit power diagnostic ultrasound imaging |
US6837854B2 (en) * | 2002-12-18 | 2005-01-04 | Barbara Ann Karmanos Cancer Institute | Methods and systems for using reference images in acoustic image processing |
US6926672B2 (en) * | 2002-12-18 | 2005-08-09 | Barbara Ann Karmanos Cancer Institute | Electret acoustic transducer array for computerized ultrasound risk evaluation system |
US8088067B2 (en) * | 2002-12-23 | 2012-01-03 | Insightec Ltd. | Tissue aberration corrections in ultrasound therapy |
WO2004060448A2 (en) * | 2003-01-03 | 2004-07-22 | Ekos Corporation | Ultrasonic catheter with axial energy field |
JP4543430B2 (en) * | 2003-01-31 | 2010-09-15 | 株式会社日立メディコ | Ultrasonic probe and ultrasonic device |
US20030191396A1 (en) * | 2003-03-10 | 2003-10-09 | Sanghvi Narendra T | Tissue treatment method and apparatus |
AU2008201641B2 (en) * | 2003-05-21 | 2008-07-10 | Paul David Syme | Method for diagnosis and treatment of vessel occlusion |
WO2004112886A2 (en) * | 2003-06-17 | 2004-12-29 | Ebr Systems, Inc. | Methods and systems for vibrational treatment of cardiac arrhythmias |
US7662099B2 (en) * | 2003-06-30 | 2010-02-16 | Ethicon, Inc. | Method and instrumentation to sense thermal lesion formation by ultrasound imaging |
US7048863B2 (en) * | 2003-07-08 | 2006-05-23 | Ashland Licensing And Intellectual Property Llc | Device and process for treating cutting fluids using ultrasound |
US7358226B2 (en) * | 2003-08-27 | 2008-04-15 | The Regents Of The University Of California | Ultrasonic concentration of drug delivery capsules |
US20090069728A1 (en) * | 2004-07-30 | 2009-03-12 | Andrew Kenneth Hoffmann | Randomic vibration for treatment of blood flow disorders |
US8734368B2 (en) | 2003-09-04 | 2014-05-27 | Simon Fraser University | Percussion assisted angiogenesis |
US8870796B2 (en) * | 2003-09-04 | 2014-10-28 | Ahof Biophysical Systems Inc. | Vibration method for clearing acute arterial thrombotic occlusions in the emergency treatment of heart attack and stroke |
US20060025683A1 (en) * | 2004-07-30 | 2006-02-02 | Ahof Biophysical Systems Inc. | Hand-held imaging probe for treatment of states of low blood perfusion |
CA2439667A1 (en) * | 2003-09-04 | 2005-03-04 | Andrew Kenneth Hoffmann | Low frequency vibration assisted blood perfusion system and apparatus |
US8721573B2 (en) | 2003-09-04 | 2014-05-13 | Simon Fraser University | Automatically adjusting contact node for multiple rib space engagement |
US20050124897A1 (en) * | 2003-12-03 | 2005-06-09 | Scimed Life Systems, Inc. | Apparatus and methods for delivering acoustic energy to body tissue |
US20110040171A1 (en) * | 2003-12-16 | 2011-02-17 | University Of Washington | Image guided high intensity focused ultrasound treatment of nerves |
BRPI0418242A (en) * | 2003-12-30 | 2007-04-17 | Liposonix Inc | transducer for ultrasound, transducer assemblies and interchangeable electronic medical instruments |
US9107590B2 (en) | 2004-01-29 | 2015-08-18 | Ekos Corporation | Method and apparatus for detecting vascular conditions with a catheter |
US7201737B2 (en) * | 2004-01-29 | 2007-04-10 | Ekos Corporation | Treatment of vascular occlusions using elevated temperatures |
US7341569B2 (en) | 2004-01-30 | 2008-03-11 | Ekos Corporation | Treatment of vascular occlusions using ultrasonic energy and microbubbles |
US7247141B2 (en) | 2004-03-08 | 2007-07-24 | Ethicon Endo-Surgery, Inc. | Intra-cavitary ultrasound medical system and method |
US9750425B2 (en) * | 2004-03-23 | 2017-09-05 | Dune Medical Devices Ltd. | Graphical user interfaces (GUI), methods and apparatus for data presentation |
US7904145B2 (en) | 2004-03-23 | 2011-03-08 | Dune Medical Devices Ltd. | Clean margin assessment tool |
US20050240123A1 (en) * | 2004-04-14 | 2005-10-27 | Mast T D | Ultrasound medical treatment system and method |
US7494467B2 (en) * | 2004-04-16 | 2009-02-24 | Ethicon Endo-Surgery, Inc. | Medical system having multiple ultrasound transducers or an ultrasound transducer and an RF electrode |
US8235909B2 (en) | 2004-05-12 | 2012-08-07 | Guided Therapy Systems, L.L.C. | Method and system for controlled scanning, imaging and/or therapy |
US7883468B2 (en) | 2004-05-18 | 2011-02-08 | Ethicon Endo-Surgery, Inc. | Medical system having an ultrasound source and an acoustic coupling medium |
US7951095B2 (en) | 2004-05-20 | 2011-05-31 | Ethicon Endo-Surgery, Inc. | Ultrasound medical system |
US7473250B2 (en) | 2004-05-21 | 2009-01-06 | Ethicon Endo-Surgery, Inc. | Ultrasound medical system and method |
US7695436B2 (en) * | 2004-05-21 | 2010-04-13 | Ethicon Endo-Surgery, Inc. | Transmit apodization of an ultrasound transducer array |
US7806839B2 (en) | 2004-06-14 | 2010-10-05 | Ethicon Endo-Surgery, Inc. | System and method for ultrasound therapy using grating lobes |
US7765001B2 (en) | 2005-08-31 | 2010-07-27 | Ebr Systems, Inc. | Methods and systems for heart failure prevention and treatments using ultrasound and leadless implantable devices |
PT1761284E (en) | 2004-06-23 | 2012-12-12 | Ashland Licensing & Intellectu | Device and method for treating fluids utilized in electrocoating processes with ultrasound |
CN101090670B (en) * | 2004-08-17 | 2010-05-26 | 特赫尼恩研究与发展基金有限公司 | Ultrasonic image-guided tissue-damaging system and method |
US9066679B2 (en) | 2004-08-31 | 2015-06-30 | University Of Washington | Ultrasonic technique for assessing wall vibrations in stenosed blood vessels |
US9011336B2 (en) * | 2004-09-16 | 2015-04-21 | Guided Therapy Systems, Llc | Method and system for combined energy therapy profile |
CA2575687A1 (en) | 2004-09-16 | 2006-03-23 | University Of Washington | Acoustic coupler using an independent water pillow with circulation for cooling a transducer |
ATE493103T1 (en) * | 2004-09-16 | 2011-01-15 | Univ Washington | NON-INTERFERENCE ULTRASONIC IMAGING DURING HIFU THERAPY USING SOFTWARE TOOLS |
US7824348B2 (en) * | 2004-09-16 | 2010-11-02 | Guided Therapy Systems, L.L.C. | System and method for variable depth ultrasound treatment |
US7393325B2 (en) | 2004-09-16 | 2008-07-01 | Guided Therapy Systems, L.L.C. | Method and system for ultrasound treatment with a multi-directional transducer |
US8234923B2 (en) * | 2004-09-20 | 2012-08-07 | Innervision Medical Technologies Inc. | Systems and methods for ultrasound imaging |
US7850611B2 (en) * | 2004-09-20 | 2010-12-14 | Innervision Medical Technologies Inc. | System and methods for improved ultrasound imaging |
US7819805B2 (en) * | 2004-09-20 | 2010-10-26 | Mgb Investments Limited Partnership | Sub-nyquist sampling of acoustic signals in ultrasound imaging |
US10864385B2 (en) | 2004-09-24 | 2020-12-15 | Guided Therapy Systems, Llc | Rejuvenating skin by heating tissue for cosmetic treatment of the face and body |
US8535228B2 (en) | 2004-10-06 | 2013-09-17 | Guided Therapy Systems, Llc | Method and system for noninvasive face lifts and deep tissue tightening |
US8444562B2 (en) | 2004-10-06 | 2013-05-21 | Guided Therapy Systems, Llc | System and method for treating muscle, tendon, ligament and cartilage tissue |
US7530958B2 (en) * | 2004-09-24 | 2009-05-12 | Guided Therapy Systems, Inc. | Method and system for combined ultrasound treatment |
US11883688B2 (en) | 2004-10-06 | 2024-01-30 | Guided Therapy Systems, Llc | Energy based fat reduction |
US11235179B2 (en) | 2004-10-06 | 2022-02-01 | Guided Therapy Systems, Llc | Energy based skin gland treatment |
EP2279696A3 (en) * | 2004-10-06 | 2014-02-26 | Guided Therapy Systems, L.L.C. | Method and system for non-invasive mastopexy |
US20060111744A1 (en) | 2004-10-13 | 2006-05-25 | Guided Therapy Systems, L.L.C. | Method and system for treatment of sweat glands |
US7530356B2 (en) * | 2004-10-06 | 2009-05-12 | Guided Therapy Systems, Inc. | Method and system for noninvasive mastopexy |
US7758524B2 (en) | 2004-10-06 | 2010-07-20 | Guided Therapy Systems, L.L.C. | Method and system for ultra-high frequency ultrasound treatment |
US8690778B2 (en) | 2004-10-06 | 2014-04-08 | Guided Therapy Systems, Llc | Energy-based tissue tightening |
US9827449B2 (en) | 2004-10-06 | 2017-11-28 | Guided Therapy Systems, L.L.C. | Systems for treating skin laxity |
KR101732144B1 (en) | 2004-10-06 | 2017-05-02 | 가이디드 테라피 시스템스, 엘.엘.씨. | Ultrasound treatment system |
US9694212B2 (en) | 2004-10-06 | 2017-07-04 | Guided Therapy Systems, Llc | Method and system for ultrasound treatment of skin |
US8133180B2 (en) | 2004-10-06 | 2012-03-13 | Guided Therapy Systems, L.L.C. | Method and system for treating cellulite |
US11207548B2 (en) | 2004-10-07 | 2021-12-28 | Guided Therapy Systems, L.L.C. | Ultrasound probe for treating skin laxity |
US11724133B2 (en) | 2004-10-07 | 2023-08-15 | Guided Therapy Systems, Llc | Ultrasound probe for treatment of skin |
US20060106434A1 (en) * | 2004-11-12 | 2006-05-18 | Padgitt Steven T | Portable time harmonic tissue stimulator and method |
US20060184070A1 (en) * | 2004-11-12 | 2006-08-17 | Hansmann Douglas R | External ultrasonic therapy |
PL1828059T3 (en) | 2004-11-17 | 2014-05-30 | Solenis Technologies Cayman Lp | Method for treating cooling fluids utilized in tire manufacturing |
KR100714682B1 (en) * | 2004-12-02 | 2007-05-04 | 삼성전자주식회사 | File system path processing device and method thereof |
US20060173387A1 (en) * | 2004-12-10 | 2006-08-03 | Douglas Hansmann | Externally enhanced ultrasonic therapy |
TWI268149B (en) * | 2004-12-29 | 2006-12-11 | Ind Tech Res Inst | Intravascular ultrasound probing device |
EP1890596B1 (en) * | 2005-03-29 | 2013-10-02 | Dune Medical Devices Ltd. | Electromagnetic sensors for tissue characterization |
JP2008536562A (en) * | 2005-04-12 | 2008-09-11 | イコス コーポレイション | Ultrasound catheter provided with a cavity forming propulsion surface |
US7571336B2 (en) * | 2005-04-25 | 2009-08-04 | Guided Therapy Systems, L.L.C. | Method and system for enhancing safety with medical peripheral device by monitoring if host computer is AC powered |
FR2886533B1 (en) * | 2005-06-03 | 2007-09-14 | Theraclion Soc Par Actions Sim | IMAGING AND PROCESSING HEAD OF LIVING ORGANS AND METHOD OF MANUFACTURING |
JP4369907B2 (en) * | 2005-07-01 | 2009-11-25 | 株式会社日立製作所 | Sonochemical treatment equipment |
US8128618B2 (en) * | 2005-08-03 | 2012-03-06 | Massachusetts Eye & Ear Infirmary | Targeted muscle ablation for reducing signs of aging |
US7837626B2 (en) * | 2005-08-05 | 2010-11-23 | Siemens Medical Solutions Usa, Inc. | Contrast agent manipulation with medical ultrasound imaging |
EP1921976A2 (en) * | 2005-08-12 | 2008-05-21 | University of Washington | Method and apparatus for preparing organs and tissues for laparoscopic surgery |
US7621873B2 (en) * | 2005-08-17 | 2009-11-24 | University Of Washington | Method and system to synchronize acoustic therapy with ultrasound imaging |
US7591996B2 (en) * | 2005-08-17 | 2009-09-22 | University Of Washington | Ultrasound target vessel occlusion using microbubbles |
US8012092B2 (en) * | 2005-08-30 | 2011-09-06 | Koninklijke Philips Electronics N.V. | Method of using a combination imaging and therapy transducer to dissolve blood clots |
WO2007026300A1 (en) * | 2005-08-30 | 2007-03-08 | Koninklijke Philips Electronics, N.V. | Combination imaging and therapy transducer with therapy transducer amplifier |
US8414494B2 (en) | 2005-09-16 | 2013-04-09 | University Of Washington | Thin-profile therapeutic ultrasound applicators |
US8057408B2 (en) | 2005-09-22 | 2011-11-15 | The Regents Of The University Of Michigan | Pulsed cavitational ultrasound therapy |
US10219815B2 (en) | 2005-09-22 | 2019-03-05 | The Regents Of The University Of Michigan | Histotripsy for thrombolysis |
US20070071683A1 (en) * | 2005-09-27 | 2007-03-29 | The Regents Of The University Of California | Ultrasonic concentration of carrier particles |
US8016757B2 (en) * | 2005-09-30 | 2011-09-13 | University Of Washington | Non-invasive temperature estimation technique for HIFU therapy monitoring using backscattered ultrasound |
WO2007047726A2 (en) | 2005-10-20 | 2007-04-26 | The General Hospital Corporation | Non-invasive treatment of fascia |
US20070233185A1 (en) | 2005-10-20 | 2007-10-04 | Thomas Anderson | Systems and methods for sealing a vascular opening |
WO2007058668A1 (en) * | 2005-11-18 | 2007-05-24 | Imarx Therapeutics, Inc. | Ultrasound apparatus and method to treat an ischemic stroke |
US7766833B2 (en) * | 2005-11-23 | 2010-08-03 | General Electric Company | Ablation array having independently activated ablation elements |
US20090221882A1 (en) * | 2005-12-08 | 2009-09-03 | Dan Gur Furman | Implantable Biosensor Assembly and Health Monitoring system and Method including same |
IL185609A0 (en) * | 2007-08-30 | 2008-01-06 | Dan Furman | Multi function senssor |
ATE520353T1 (en) * | 2005-12-14 | 2011-09-15 | Koninkl Philips Electronics Nv | CONVERTER CUFF FOR DELIVERY AND APPLICATION OF HIGH-INTENSITY FOCUSED ULTRASOUND TO CONTROL BLEEDING DUE TO SEVERED LIMBS |
US20070239011A1 (en) * | 2006-01-13 | 2007-10-11 | Mirabilis Medica, Inc. | Apparatus for delivering high intensity focused ultrasound energy to a treatment site internal to a patient's body |
US8105239B2 (en) | 2006-02-06 | 2012-01-31 | Maui Imaging, Inc. | Method and apparatus to visualize the coronary arteries using ultrasound |
CA2649119A1 (en) * | 2006-04-13 | 2007-12-13 | Mirabilis Medica, Inc. | Methods and apparatus for the treatment of menometrorrhagia, endometrial pathology, and cervical neoplasia using high intensity focused ultrasound energy |
WO2007127176A2 (en) | 2006-04-24 | 2007-11-08 | Ekos Corporation | Ultrasound therapy system |
US20080154181A1 (en) * | 2006-05-05 | 2008-06-26 | Khanna Rohit K | Central nervous system ultrasonic drain |
CN101500650B (en) * | 2006-08-11 | 2012-08-08 | 皇家飞利浦电子股份有限公司 | Ultrasound system for cerebral blood flow imaging and microbubble-enhanced blood clot lysis |
US9566454B2 (en) | 2006-09-18 | 2017-02-14 | Guided Therapy Systems, Llc | Method and sysem for non-ablative acne treatment and prevention |
WO2008036773A1 (en) * | 2006-09-19 | 2008-03-27 | Guided Therapy Systems, Llc | Method and system for treating muscle, tendon, ligament and cartilage tissue |
US20100041989A1 (en) * | 2006-09-29 | 2010-02-18 | The Trustees Of The University Of Pennsylvania | Use of ultrasound as an antivascular agent |
US9241683B2 (en) * | 2006-10-04 | 2016-01-26 | Ardent Sound Inc. | Ultrasound system and method for imaging and/or measuring displacement of moving tissue and fluid |
EP2088932B1 (en) | 2006-10-25 | 2020-04-08 | Maui Imaging, Inc. | Method and apparatus to produce ultrasonic images using multiple apertures |
US8192363B2 (en) | 2006-10-27 | 2012-06-05 | Ekos Corporation | Catheter with multiple ultrasound radiating members |
JP5670635B2 (en) * | 2006-11-28 | 2015-02-18 | コーニンクレッカ フィリップス エヌ ヴェ | Apparatus for 3D ultrasound imaging and therapy |
US20090048518A1 (en) * | 2006-12-10 | 2009-02-19 | Cardio Art Technologies Ltd. | Doppler motion sensor apparatus and method of using same |
EP2111261B1 (en) | 2007-01-08 | 2015-04-15 | Ekos Corporation | Power parameters for ultrasonic catheter |
US10182833B2 (en) | 2007-01-08 | 2019-01-22 | Ekos Corporation | Power parameters for ultrasonic catheter |
US8147423B2 (en) * | 2007-03-01 | 2012-04-03 | Dune Medical Devices, Ltd. | Tissue-characterization system and method |
US8870771B2 (en) * | 2007-05-04 | 2014-10-28 | Barbara Ann Karmanos Cancer Institute | Method and apparatus for categorizing breast density and assessing cancer risk utilizing acoustic parameters |
US10201324B2 (en) | 2007-05-04 | 2019-02-12 | Delphinus Medical Technologies, Inc. | Patient interface system |
DK2152167T3 (en) | 2007-05-07 | 2018-12-10 | Guided Therapy Systems Llc | Methods and systems for coupling and focusing acoustic energy using a coupling element |
TWI526233B (en) | 2007-05-07 | 2016-03-21 | 指導治療系統股份有限公司 | Methods and systems for modulating medicants using acoustic energy |
US20150174388A1 (en) | 2007-05-07 | 2015-06-25 | Guided Therapy Systems, Llc | Methods and Systems for Ultrasound Assisted Delivery of a Medicant to Tissue |
US9044568B2 (en) | 2007-06-22 | 2015-06-02 | Ekos Corporation | Method and apparatus for treatment of intracranial hemorrhages |
US8052604B2 (en) * | 2007-07-31 | 2011-11-08 | Mirabilis Medica Inc. | Methods and apparatus for engagement and coupling of an intracavitory imaging and high intensity focused ultrasound probe |
US9282945B2 (en) | 2009-04-14 | 2016-03-15 | Maui Imaging, Inc. | Calibration of ultrasound probes |
US9895158B2 (en) | 2007-10-26 | 2018-02-20 | University Of Virginia Patent Foundation | Method and apparatus for accelerated disintegration of blood clot |
US8622911B2 (en) * | 2007-10-26 | 2014-01-07 | University Of Virginia Patent Foundation | System for treatment and imaging using ultrasonic energy and microbubbles and related method thereof |
US8439907B2 (en) * | 2007-11-07 | 2013-05-14 | Mirabilis Medica Inc. | Hemostatic tissue tunnel generator for inserting treatment apparatus into tissue of a patient |
US8187270B2 (en) * | 2007-11-07 | 2012-05-29 | Mirabilis Medica Inc. | Hemostatic spark erosion tissue tunnel generator with integral treatment providing variable volumetric necrotization of tissue |
US20090254008A1 (en) * | 2008-01-29 | 2009-10-08 | Shields Jr Donald J | Systems, devices, and methods to concurrently deliver ultrasound waves having thermal and non-thermal effects |
US9079219B2 (en) * | 2008-02-29 | 2015-07-14 | Stc.Unm | Therapeutic ultrasound transducer chip with integrated ultrasound imager and methods of making and using the same |
US20090240148A1 (en) * | 2008-03-19 | 2009-09-24 | University Of Southern California | Ultrasonic apparatus and method for real-time simultaneous therapy and diagnosis |
US8942781B2 (en) | 2008-04-09 | 2015-01-27 | Universite Pierre Et Marie Curie (Paris 6) | Medical system comprising a percutaneous probe |
CA2722662A1 (en) * | 2008-05-12 | 2009-11-19 | Cardio Art Technologies, Ltd. | Integrated heart monitoring device and method of using same |
DK2282675T3 (en) | 2008-06-06 | 2016-05-17 | Ulthera Inc | Cosmetic treatment and imaging system |
GB0811856D0 (en) * | 2008-06-27 | 2008-07-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
US20090326372A1 (en) * | 2008-06-30 | 2009-12-31 | Darlington Gregory | Compound Imaging with HIFU Transducer and Use of Pseudo 3D Imaging |
WO2010009141A1 (en) * | 2008-07-14 | 2010-01-21 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Methods and devices for modulating cellular activity using ultrasound |
US9248318B2 (en) | 2008-08-06 | 2016-02-02 | Mirabilis Medica Inc. | Optimization and feedback control of HIFU power deposition through the analysis of detected signal characteristics |
US8216161B2 (en) * | 2008-08-06 | 2012-07-10 | Mirabilis Medica Inc. | Optimization and feedback control of HIFU power deposition through the frequency analysis of backscattered HIFU signals |
JP5666446B2 (en) | 2008-08-08 | 2015-02-12 | マウイ イマギング,インコーポレーテッド | Image forming method using multi-aperture medical ultrasonic technology and synchronization method of add-on system |
US9050449B2 (en) * | 2008-10-03 | 2015-06-09 | Mirabilis Medica, Inc. | System for treating a volume of tissue with high intensity focused ultrasound |
US8845559B2 (en) * | 2008-10-03 | 2014-09-30 | Mirabilis Medica Inc. | Method and apparatus for treating tissues with HIFU |
CA2748362A1 (en) | 2008-12-24 | 2010-07-01 | Michael H. Slayton | Methods and systems for fat reduction and/or cellulite treatment |
KR20110127736A (en) * | 2009-03-06 | 2011-11-25 | 미라빌리스 메디카 인코포레이티드 | Ultrasound treatment and imaging applicator |
KR101659723B1 (en) | 2009-04-14 | 2016-09-26 | 마우이 이미징, 인코포레이티드 | Multiple aperture ultrasound array alignment fixture |
WO2010120913A2 (en) * | 2009-04-14 | 2010-10-21 | Maui Imaging, Inc. | Universal multiple aperture medical ultrasound probe |
PL2448636T3 (en) | 2009-07-03 | 2014-11-28 | Ekos Corp | Power parameters for ultrasonic catheter |
AU2010284313B2 (en) | 2009-08-17 | 2016-01-28 | Histosonics, Inc. | Disposable acoustic coupling medium container |
JP5726191B2 (en) | 2009-08-26 | 2015-05-27 | リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Apparatus and method using control of bubble turbidity cavitation phenomenon during fracture of ureteral stones |
WO2011028603A2 (en) | 2009-08-26 | 2011-03-10 | The Regents Of The University Of Michigan | Micromanipulator control arm for therapeutic and imaging ultrasound transducers |
US8460269B2 (en) * | 2009-09-14 | 2013-06-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Directed cell-based therapy using microbubble tagged cells |
US8539813B2 (en) | 2009-09-22 | 2013-09-24 | The Regents Of The University Of Michigan | Gel phantoms for testing cavitational ultrasound (histotripsy) transducers |
US20110092880A1 (en) | 2009-10-12 | 2011-04-21 | Michael Gertner | Energetic modulation of nerves |
US8295912B2 (en) | 2009-10-12 | 2012-10-23 | Kona Medical, Inc. | Method and system to inhibit a function of a nerve traveling with an artery |
US9119951B2 (en) | 2009-10-12 | 2015-09-01 | Kona Medical, Inc. | Energetic modulation of nerves |
US8469904B2 (en) | 2009-10-12 | 2013-06-25 | Kona Medical, Inc. | Energetic modulation of nerves |
US8517962B2 (en) | 2009-10-12 | 2013-08-27 | Kona Medical, Inc. | Energetic modulation of nerves |
US8986211B2 (en) | 2009-10-12 | 2015-03-24 | Kona Medical, Inc. | Energetic modulation of nerves |
US20160059044A1 (en) | 2009-10-12 | 2016-03-03 | Kona Medical, Inc. | Energy delivery to intraparenchymal regions of the kidney to treat hypertension |
US9174065B2 (en) | 2009-10-12 | 2015-11-03 | Kona Medical, Inc. | Energetic modulation of nerves |
US8986231B2 (en) | 2009-10-12 | 2015-03-24 | Kona Medical, Inc. | Energetic modulation of nerves |
US20110118600A1 (en) | 2009-11-16 | 2011-05-19 | Michael Gertner | External Autonomic Modulation |
MX2012004815A (en) * | 2009-10-24 | 2012-06-25 | Syneron Medical Ltd | Method and apparatus for real time monitoring of tissue layers. |
US20110130615A1 (en) * | 2009-12-02 | 2011-06-02 | Mishelevich David J | Multi-modality neuromodulation of brain targets |
US20110112394A1 (en) * | 2009-11-11 | 2011-05-12 | Mishelevich David J | Neuromodulation of deep-brain targets using focused ultrasound |
US20110190668A1 (en) * | 2010-02-03 | 2011-08-04 | Mishelevich David J | Ultrasound neuromodulation of the sphenopalatine ganglion |
US20110178442A1 (en) * | 2010-01-18 | 2011-07-21 | Mishelevich David J | Patient feedback for control of ultrasound deep-brain neuromodulation |
US8715186B2 (en) | 2009-11-24 | 2014-05-06 | Guided Therapy Systems, Llc | Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy |
WO2011091160A1 (en) * | 2010-01-20 | 2011-07-28 | Henry Wu | Custom-formulated phospholipid microbubbles and methods and uses thereof |
CN102869301B (en) | 2010-02-12 | 2016-06-29 | 戴尔菲纳斯医疗科技公司 | The method characterizing the tissue of patient |
CN102843959B (en) | 2010-02-12 | 2014-11-12 | 戴尔菲纳斯医疗科技公司 | Method of characterizing the pathological response of tissue to a treatmant plan |
US8740835B2 (en) | 2010-02-17 | 2014-06-03 | Ekos Corporation | Treatment of vascular occlusions using ultrasonic energy and microbubbles |
KR102121040B1 (en) | 2010-02-18 | 2020-06-09 | 마우이 이미징, 인코포레이티드 | Method of constructing an ultrasound image and multi-aperture ultrasound imaging system therefor |
US8206307B2 (en) * | 2010-03-10 | 2012-06-26 | Dbmedx Inc. | Ultrasound imaging probe and method |
WO2011146138A2 (en) | 2010-05-21 | 2011-11-24 | Misonix Incorporated | Dual-mode piezocomposite ultrasonic transducer |
KR20200004466A (en) | 2010-08-02 | 2020-01-13 | 가이디드 테라피 시스템스, 엘.엘.씨. | System and Method for Ultrasound Treatment |
US9504446B2 (en) | 2010-08-02 | 2016-11-29 | Guided Therapy Systems, Llc | Systems and methods for coupling an ultrasound source to tissue |
JP5933549B2 (en) | 2010-08-18 | 2016-06-08 | ミラビリス メディカ インク | HIFU applicator |
US10888657B2 (en) | 2010-08-27 | 2021-01-12 | Ekos Corporation | Method and apparatus for treatment of intracranial hemorrhages |
CN102397629A (en) * | 2010-09-09 | 2012-04-04 | 李陶 | Pulse type ultrasound microbubble treatment device and method for opening prostate barrier |
WO2012051308A2 (en) | 2010-10-13 | 2012-04-19 | Maui Imaging, Inc. | Concave ultrasound transducers and 3d arrays |
WO2012051305A2 (en) | 2010-10-13 | 2012-04-19 | Mau Imaging, Inc. | Multiple aperture probe internal apparatus and cable assemblies |
US8857438B2 (en) | 2010-11-08 | 2014-10-14 | Ulthera, Inc. | Devices and methods for acoustic shielding |
JP5192532B2 (en) * | 2010-11-18 | 2013-05-08 | 学校法人慈恵大学 | Medical ultrasonic transducer |
US20120143042A1 (en) * | 2010-12-06 | 2012-06-07 | Palmeri Mark L | Ultrasound Methods, Systems and Computer Program Products for Imaging Fluids Using Acoustic Radiation Force |
KR101120589B1 (en) * | 2011-02-28 | 2012-03-09 | 동국대학교 산학협력단 | A pulse generating apparatus for ultrasonic diagnosis and treatment |
EP2521593B1 (en) * | 2011-03-15 | 2015-12-09 | Kona Medical, Inc. | Energetic modulation of nerves |
US11458290B2 (en) | 2011-05-11 | 2022-10-04 | Ekos Corporation | Ultrasound system |
KR101885378B1 (en) * | 2011-06-10 | 2018-08-29 | 엘지전자 주식회사 | Portable defibrillator based on ultrasound |
US9452302B2 (en) | 2011-07-10 | 2016-09-27 | Guided Therapy Systems, Llc | Systems and methods for accelerating healing of implanted material and/or native tissue |
KR20140047709A (en) | 2011-07-11 | 2014-04-22 | 가이디드 테라피 시스템스, 엘.엘.씨. | Systems and methods for coupling an ultrasound source to tissue |
WO2013015514A1 (en) * | 2011-07-26 | 2013-01-31 | Chae Hee Cheon | Medical ultrasonic apparatus for efficiently transmitting pvdf ultrasonic acoustic output to the human body |
EP2736468B1 (en) | 2011-07-27 | 2016-04-27 | Université Pierre et Marie Curie (Paris 6) | Device for treating the sensory capacity of a person |
US9144694B2 (en) | 2011-08-10 | 2015-09-29 | The Regents Of The University Of Michigan | Lesion generation through bone using histotripsy therapy without aberration correction |
US9042201B2 (en) | 2011-10-21 | 2015-05-26 | Thync, Inc. | Method and system for direct communication |
TW201336478A (en) | 2011-12-01 | 2013-09-16 | Maui Imaging Inc | Motion detection using ping-based and multiple aperture doppler ultrasound |
WO2013101988A1 (en) | 2011-12-29 | 2013-07-04 | Maui Imaging, Inc. | M-mode ultrasound imaging of arbitrary paths |
WO2013100232A1 (en) * | 2011-12-29 | 2013-07-04 | 알피니언메디칼시스템 주식회사 | Method using transmitted and received signals for forming ultrasonic images for ultrasonic diagnosis, and high intensity focused ultrasonic therapeutic device performing same |
KR102134763B1 (en) | 2012-02-21 | 2020-07-16 | 마우이 이미징, 인코포레이티드 | Determining material stiffness using multiple aperture ultrasound |
KR101330901B1 (en) * | 2012-02-23 | 2013-11-18 | 인하대학교 산학협력단 | Ultrasonic treatment device |
EP2833791B1 (en) | 2012-03-26 | 2022-12-21 | Maui Imaging, Inc. | Methods for improving ultrasound image quality by applying weighting factors |
US9263663B2 (en) | 2012-04-13 | 2016-02-16 | Ardent Sound, Inc. | Method of making thick film transducer arrays |
US9049783B2 (en) | 2012-04-13 | 2015-06-02 | Histosonics, Inc. | Systems and methods for obtaining large creepage isolation on printed circuit boards |
EP2844343B1 (en) | 2012-04-30 | 2018-11-21 | The Regents Of The University Of Michigan | Ultrasound transducer manufacturing using rapid-prototyping method |
EP2857066A4 (en) * | 2012-05-29 | 2016-03-23 | Lissot Mailin Auxiliadora Franco | Method and apparatus for treating periprosthetic capsular contracture |
KR101357853B1 (en) * | 2012-06-04 | 2014-02-06 | 동국대학교 산학협력단 | Apparatus and method for removing therapeutic interference signals for simultaneous ultrasound therapy and diagnosis |
WO2014004912A1 (en) * | 2012-06-28 | 2014-01-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and devices for ultrasound contrast-assisted therapy |
US9113825B2 (en) * | 2012-07-10 | 2015-08-25 | Fujifilm Sonosite, Inc. | Ultrasonic probe and aligned needle guide system |
CN104620128B (en) | 2012-08-10 | 2017-06-23 | 毛伊图像公司 | The calibration of multiple aperture ultrasonic probe |
KR102176319B1 (en) | 2012-08-21 | 2020-11-09 | 마우이 이미징, 인코포레이티드 | Ultrasound imaging system memory architecture |
WO2014036170A1 (en) | 2012-08-29 | 2014-03-06 | Thync, Inc. | Systems and devices for coupling ultrasound energy to a body |
US9763641B2 (en) | 2012-08-30 | 2017-09-19 | Delphinus Medical Technologies, Inc. | Method and system for imaging a volume of tissue with tissue boundary detection |
US9510802B2 (en) | 2012-09-21 | 2016-12-06 | Guided Therapy Systems, Llc | Reflective ultrasound technology for dermatological treatments |
US20140100459A1 (en) | 2012-10-05 | 2014-04-10 | The Regents Of The University Of Michigan | Bubble-induced color doppler feedback during histotripsy |
US20140128734A1 (en) * | 2012-11-05 | 2014-05-08 | Ekos Corporation | Catheter systems and methods |
CN204637350U (en) | 2013-03-08 | 2015-09-16 | 奥赛拉公司 | Aesthstic imaging and processing system, multifocal processing system and perform the system of aesthetic procedure |
US9510806B2 (en) | 2013-03-13 | 2016-12-06 | Maui Imaging, Inc. | Alignment of ultrasound transducer arrays and multiple aperture probe assembly |
US10123770B2 (en) | 2013-03-13 | 2018-11-13 | Delphinus Medical Technologies, Inc. | Patient support system |
US9101745B2 (en) | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
KR20150126611A (en) | 2013-03-14 | 2015-11-12 | 에코스 코퍼레이션 | Method and apparatus for drug delivery to a target site |
US10561862B2 (en) | 2013-03-15 | 2020-02-18 | Guided Therapy Systems, Llc | Ultrasound treatment device and methods of use |
US10035009B2 (en) | 2013-04-15 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods for treating pancreatic cancer |
JP6600304B2 (en) | 2013-07-03 | 2019-10-30 | ヒストソニックス,インコーポレーテッド | Optimized histotripsy excitation sequence for bubble cloud formation using shock scattering |
BR112015032732B1 (en) * | 2013-07-03 | 2022-05-17 | Bracco Suisse S.A. | Ultrasonic stroke treatment system |
US11432900B2 (en) | 2013-07-03 | 2022-09-06 | Histosonics, Inc. | Articulating arm limiter for cavitational ultrasound therapy system |
CN103330578B (en) * | 2013-07-19 | 2015-05-27 | 乐普(北京)医疗器械股份有限公司 | Approximate-circumference type ultrasonic ablation catheter |
WO2015027164A1 (en) | 2013-08-22 | 2015-02-26 | The Regents Of The University Of Michigan | Histotripsy using very short ultrasound pulses |
US9883848B2 (en) | 2013-09-13 | 2018-02-06 | Maui Imaging, Inc. | Ultrasound imaging using apparent point-source transmit transducer |
JP6325850B2 (en) * | 2014-03-14 | 2018-05-16 | 公立大学法人大阪府立大学 | Fat diagnostic equipment |
SG11201608691YA (en) | 2014-04-18 | 2016-11-29 | Ulthera Inc | Band transducer ultrasound therapy |
US10143443B2 (en) | 2014-05-05 | 2018-12-04 | Delphinus Medical Technologies, Inc. | Method for representing tissue stiffness |
US10743837B2 (en) | 2014-08-04 | 2020-08-18 | Delphinus Medical Technologies, Inc. | Ultrasound waveform tomography method and system |
US10285667B2 (en) | 2014-08-05 | 2019-05-14 | Delphinus Medical Technologies, Inc. | Method for generating an enhanced image of a volume of tissue |
WO2016028787A1 (en) | 2014-08-18 | 2016-02-25 | Maui Imaging, Inc. | Network-based ultrasound imaging system |
WO2016038696A1 (en) * | 2014-09-10 | 2016-03-17 | 株式会社日立製作所 | Ultrasound irradiation device |
US10092742B2 (en) | 2014-09-22 | 2018-10-09 | Ekos Corporation | Catheter system |
JP6412275B2 (en) * | 2014-10-17 | 2018-10-24 | ユニバーシティ オブ ワシントンUniversity of Washington | Widely focused ultrasonic propulsion probe, system and method |
US10925579B2 (en) | 2014-11-05 | 2021-02-23 | Otsuka Medical Devices Co., Ltd. | Systems and methods for real-time tracking of a target tissue using imaging before and during therapy delivery |
JP6657225B2 (en) | 2014-12-19 | 2020-03-04 | ユニヴェルシテ ピエール エ マリー キュリー(パリ シス)Universite Pierre Et Marie Curie (Paris Vi) | Implantable ultrasound generating therapy device for treatment of the brain, apparatus comprising such a device, and method of implementing such a device |
EA201791437A1 (en) | 2014-12-31 | 2017-12-29 | Лантеус Медикал Имэджинг, Инк. | COMPOSITIONS OF MICROSPHERE WITH GAS DISTRIBUTED IN LIPID AND RELATED METHODS |
GB201501923D0 (en) * | 2015-02-05 | 2015-03-25 | Ionix Advanced Technologies Ltd | Piezoelectric transducers |
CN107530555A (en) * | 2015-03-30 | 2018-01-02 | 皇家飞利浦有限公司 | The ultrasound transducer array disposed and monitored for ultrasound thrombolysis |
EP3307388B1 (en) | 2015-06-10 | 2022-06-22 | Ekos Corporation | Ultrasound catheter |
JP6979882B2 (en) | 2015-06-24 | 2021-12-15 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Tissue disruption therapy systems and methods for the treatment of brain tissue |
CN105249995B (en) * | 2015-10-29 | 2017-10-10 | 杭州迪比声学技术有限公司 | The localization method of the extracorporeal shock-wave lithotomy instrument for the treatment of site is positioned using ultrasonic wave |
CN105411625B (en) * | 2015-12-28 | 2019-06-07 | 中国科学院苏州生物医学工程技术研究所 | Diagnosis and treatment integrative ultrasonic system based on capacitance type micromachined ultrasonic energy converter planar battle array |
KR102615327B1 (en) | 2016-01-18 | 2023-12-18 | 얼테라, 인크 | Compact ultrasonic device with annular ultrasonic array locally electrically connected to a flexible printed circuit board and method of assembling the same |
US10856846B2 (en) | 2016-01-27 | 2020-12-08 | Maui Imaging, Inc. | Ultrasound imaging with sparse array probes |
WO2017153799A1 (en) | 2016-03-11 | 2017-09-14 | Universite Pierre Et Marie Curie (Paris 6) | External ultrasound generating treating device for spinal cord and spinal nerves treatment, apparatus comprising such device and method implementing such device |
CA3016001C (en) | 2016-03-11 | 2023-08-15 | Sorbonne Universite | Implantable ultrasound generating treating device for spinal cord and/or spinal nerve treatment, apparatus comprising such device and method |
TWI578963B (en) * | 2016-04-29 | 2017-04-21 | 長庚大學 | An ultrasound analysis apparatus |
JP2019515936A (en) | 2016-05-04 | 2019-06-13 | ランセウス メディカル イメージング, インコーポレイテッド | Methods and devices for preparing ultrasound contrast agents |
US10493172B2 (en) | 2016-06-02 | 2019-12-03 | California Institute Of Technology | Gas-filled structures and related compositions, methods and systems to image a target site |
US9789210B1 (en) | 2016-07-06 | 2017-10-17 | Lantheus Medical Imaging, Inc. | Methods for making ultrasound contrast agents |
CN105943087B (en) * | 2016-07-26 | 2019-03-19 | 飞依诺科技(苏州)有限公司 | The image processing method and processing system of ultrasonic microbubble cavitation device |
KR102593310B1 (en) | 2016-08-16 | 2023-10-25 | 얼테라, 인크 | Ultrasound imaging system configured to reduce imaging misalignment, ultrasound imaging module, and method for reducing imaging misalignment |
KR101847295B1 (en) * | 2016-10-31 | 2018-05-28 | 재단법인 다차원 스마트 아이티 융합시스템 연구단 | User interface apparatus using transmitting and receiving supersound signal |
US10449349B2 (en) * | 2016-12-14 | 2019-10-22 | L'oreal | Systems, devices, and methods including encapsulated cosmetics |
US11883235B2 (en) * | 2017-08-15 | 2024-01-30 | Philips Image Guided Therapy Corporation | Phased array imaging and therapy intraluminal ultrasound device |
WO2019034500A1 (en) | 2017-08-15 | 2019-02-21 | Koninklijke Philips N.V. | Frequency-tunable intraluminal ultrasound device |
US11944849B2 (en) | 2018-02-20 | 2024-04-02 | Ulthera, Inc. | Systems and methods for combined cosmetic treatment of cellulite with ultrasound |
CN108814643A (en) * | 2018-04-04 | 2018-11-16 | 飞依诺科技(苏州)有限公司 | A kind of ultrasonic scanning method and apparatus |
KR102174627B1 (en) * | 2018-05-11 | 2020-11-05 | 서강대학교산학협력단 | Apparatus and method for eliminating ultrasound noise for realtime ultrasound monitoring |
WO2020033764A1 (en) * | 2018-08-08 | 2020-02-13 | Craniovation, Inc. | Tissue treatment with sensitizer and light and/or sound |
CN109124687B (en) * | 2018-08-30 | 2021-05-14 | 飞依诺科技(苏州)有限公司 | Ultrasonic device and medical equipment for simultaneously carrying out ultrasonic diagnosis and treatment |
KR102249727B1 (en) * | 2018-11-15 | 2021-05-10 | 주식회사 오스테오시스 | Ultrasonic transducer |
US11813484B2 (en) | 2018-11-28 | 2023-11-14 | Histosonics, Inc. | Histotripsy systems and methods |
US11761008B2 (en) | 2019-01-07 | 2023-09-19 | California Institute Of Technology | Gas vesicle expression systems, gas vesicle constructs and related genetic circuits, vectors, mammalian cells, hosts, compositions, methods and systems |
WO2020146367A1 (en) | 2019-01-07 | 2020-07-16 | California Institute Of Technology | Burst ultrasound reconstruction with signal templates and related methods and systems |
CA3128067A1 (en) | 2019-02-13 | 2020-08-20 | Alpheus Medical, Inc. | Non-invasive sonodynamic therapy |
WO2020198728A1 (en) * | 2019-03-28 | 2020-10-01 | California Institute Of Technology | Compositions, methods and systems for gas vesicle based cavitation |
US11793863B2 (en) | 2019-04-26 | 2023-10-24 | University of Pittsburgh—of the Commonwealth System of Higher Education | Functionalized microbubble embodiments for ultrasound-mediated treatment and methods of making and using the same |
EP4096782A4 (en) | 2020-01-28 | 2024-02-14 | Univ Michigan Regents | Systems and methods for histotripsy immunosensitization |
EP4205710A1 (en) * | 2021-12-30 | 2023-07-05 | Paul Hartmann Aktiengesellschaft | Wound dressing for a wound |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3640122A (en) * | 1969-11-20 | 1972-02-08 | Bethlehem Steel Corp | Ultrasonic defect signal discriminator |
US3735755A (en) * | 1971-06-28 | 1973-05-29 | Interscience Research Inst | Noninvasive surgery method and apparatus |
US3936791A (en) * | 1973-09-13 | 1976-02-03 | The Commonwealth Of Australia | Linear array ultrasonic transducer |
US4276885A (en) * | 1979-05-04 | 1981-07-07 | Rasor Associates, Inc | Ultrasonic image enhancement |
US4385255A (en) * | 1979-11-02 | 1983-05-24 | Yokogawa Electric Works, Ltd. | Linear array ultrasonic transducer |
US4484569A (en) * | 1981-03-13 | 1984-11-27 | Riverside Research Institute | Ultrasonic diagnostic and therapeutic transducer assembly and method for using |
EP0068961A3 (en) * | 1981-06-26 | 1983-02-02 | Thomson-Csf | Apparatus for the local heating of biological tissue |
DE3141641A1 (en) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | ULTRASONIC CONTRAST AGENTS AND THEIR PRODUCTION |
EP0111386B1 (en) * | 1982-10-26 | 1987-11-19 | University Of Aberdeen | Ultrasound hyperthermia unit |
US4492120A (en) * | 1983-03-18 | 1985-01-08 | Irex Corporation | Dual function ultrasonic transducer assembly |
FR2563725B1 (en) * | 1984-05-03 | 1988-07-15 | Dory Jacques | APPARATUS FOR EXAMINING AND LOCATING ULTRASONIC TUMORS WITH A LOCALIZED HYPERTHERMAL TREATMENT DEVICE |
US5143073A (en) * | 1983-12-14 | 1992-09-01 | Edap International, S.A. | Wave apparatus system |
US5150712A (en) * | 1983-12-14 | 1992-09-29 | Edap International, S.A. | Apparatus for examining and localizing tumors using ultra sounds, comprising a device for localized hyperthermia treatment |
US4620546A (en) * | 1984-06-30 | 1986-11-04 | Kabushiki Kaisha Toshiba | Ultrasound hyperthermia apparatus |
JPS6131135A (en) * | 1984-07-25 | 1986-02-13 | 株式会社東芝 | Ultrasonic diagnostic apparatus |
JPS61209643A (en) * | 1985-03-15 | 1986-09-17 | 株式会社東芝 | Ultrasonic diagnostic and medical treatment apparatus |
US4865042A (en) * | 1985-08-16 | 1989-09-12 | Hitachi, Ltd. | Ultrasonic irradiation system |
US4787394A (en) * | 1986-04-24 | 1988-11-29 | Kabushiki Kaisha Toshiba | Ultrasound therapy apparatus |
DE3704909A1 (en) * | 1987-02-17 | 1988-08-25 | Wolf Gmbh Richard | DEVICE FOR SPACIOUS LOCATION AND DESTRUCTION OF INTERIOR OBJECTS WITH ULTRASOUND |
US4932414A (en) * | 1987-11-02 | 1990-06-12 | Cornell Research Foundation, Inc. | System of therapeutic ultrasound and real-time ultrasonic scanning |
DE3741201A1 (en) * | 1987-12-02 | 1989-06-15 | Schering Ag | ULTRASONIC PROCESS AND METHOD FOR IMPLEMENTING IT |
US5158071A (en) * | 1988-07-01 | 1992-10-27 | Hitachi, Ltd. | Ultrasonic apparatus for therapeutical use |
NL8801776A (en) * | 1988-07-13 | 1990-02-01 | Optische Ind De Oude Delft Nv | ULTRASONIC TRANSDUCER INCLUDING AT LEAST ONE ROW OF ULTRASONIC ELEMENTS. |
US5410516A (en) * | 1988-09-01 | 1995-04-25 | Schering Aktiengesellschaft | Ultrasonic processes and circuits for performing them |
US5435311A (en) * | 1989-06-27 | 1995-07-25 | Hitachi, Ltd. | Ultrasound therapeutic system |
US5149319A (en) * | 1990-09-11 | 1992-09-22 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids |
US5209720A (en) * | 1989-12-22 | 1993-05-11 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5215680A (en) * | 1990-07-10 | 1993-06-01 | Cavitation-Control Technology, Inc. | Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles |
DE4205030C2 (en) * | 1991-02-28 | 1997-04-03 | Hitachi Ltd | Therapeutic ultrasound device |
GB9106673D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
WO1992021382A1 (en) * | 1991-06-03 | 1992-12-10 | Holmes, Michael, John | Improvements in or relating to contrast agents |
DE4240082C1 (en) * | 1992-11-28 | 1994-04-21 | Erno Raumfahrttechnik Gmbh | Heat pipe |
DE4241161C2 (en) * | 1992-12-07 | 1995-04-13 | Siemens Ag | Acoustic therapy facility |
DE4302537C1 (en) * | 1993-01-29 | 1994-04-28 | Siemens Ag | Ultrasound imaging and therapy device - generates imaging waves and focussed treatment waves having two differing frequencies for location and treatment of e.g tumours |
DE4302538C1 (en) * | 1993-01-29 | 1994-04-07 | Siemens Ag | Ultrasonic therapy device for tumour treatment lithotripsy or osteorestoration - with ultrasonic imaging and ultrasonic treatment modes using respective acoustic wave frequencies |
DE69432510T2 (en) * | 1993-12-24 | 2003-12-24 | Olympus Optical Co | Device for ultrasound diagnosis and treatment, wherein the focal point of the therapeutic ultrasound wave is locked in a predetermined position within the ultrasound observation area |
US7625093B2 (en) | 2005-03-29 | 2009-12-01 | Seiko Epson Corporation | Image display device having a plurality of basic-color projection units |
-
1995
- 1995-06-06 US US08/468,052 patent/US5558092A/en not_active Expired - Lifetime
-
1996
- 1996-05-24 WO PCT/US1996/007621 patent/WO1996039079A1/en not_active Application Discontinuation
- 1996-05-24 CN CN96194441.2A patent/CN1186420A/en active Pending
- 1996-05-24 AU AU58756/96A patent/AU711788B2/en not_active Ceased
- 1996-05-24 EP EP96920466A patent/EP0836420A4/en not_active Withdrawn
- 1996-05-24 CA CA002220756A patent/CA2220756A1/en not_active Abandoned
- 1996-05-24 JP JP9500706A patent/JPH11506636A/en active Pending
-
2007
- 2007-04-18 JP JP2007109740A patent/JP2007289693A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0836420A1 (en) | 1998-04-22 |
JPH11506636A (en) | 1999-06-15 |
EP0836420A4 (en) | 1999-12-08 |
WO1996039079A1 (en) | 1996-12-12 |
JP2007289693A (en) | 2007-11-08 |
CN1186420A (en) | 1998-07-01 |
US5558092A (en) | 1996-09-24 |
AU711788B2 (en) | 1999-10-21 |
AU5875696A (en) | 1996-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5558092A (en) | Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously | |
CA2773181C (en) | Systems, methods, and computer readable media for high-frequency contrast imaging and image-guided therapeutics | |
EP1793741B1 (en) | Intravascular ultrasound techniques | |
US5906580A (en) | Ultrasound system and method of administering ultrasound including a plurality of multi-layer transducer elements | |
CN110314834B (en) | Ultrasonic transducer and preparation method thereof | |
US10926112B2 (en) | Devices and methods for the ultrasound treatment of ischemic stroke | |
US6623430B1 (en) | Method and apparatus for safety delivering medicants to a region of tissue using imaging, therapy and temperature monitoring ultrasonic system | |
US9642634B2 (en) | Pulsed cavitational ultrasound therapy | |
US9198680B2 (en) | Combination imaging and therapy transducer with therapy transducer amplifier | |
JP7203824B2 (en) | Intraluminal ultrasound device with adjustable frequency | |
JPH03297475A (en) | Controlling method for emission of medicine by means of resonance sound wave | |
US20080319316A1 (en) | Combination Imaging and Therapy Transducer | |
EP3386589A1 (en) | Interleaved beam pattern for sonothrombolysis and other vascular acoustic resonator mediated therapies | |
AU736153B2 (en) | Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously | |
Wu | Design, Fabrication and Characterization of Ultrasound Transducers and Arrays for Biomedical Imaging and Therapy | |
Mannaris | Ultrasound enhanced drug delivery: pressure and temperature activation approaches |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |